Molecular Functions of MLL PHD3 Binding to Its Ligands Cyp33 and H3K4Me3 by Raman, Gayathree
Loyola University Chicago
Loyola eCommons
Dissertations Theses and Dissertations
2013
Molecular Functions of MLL PHD3 Binding to Its
Ligands Cyp33 and H3K4Me3
Gayathree Raman
Loyola University Chicago
This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in
Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2013 Gayathree Raman
Recommended Citation
Raman, Gayathree, "Molecular Functions of MLL PHD3 Binding to Its Ligands Cyp33 and H3K4Me3" (2013). Dissertations. Paper
540.
http://ecommons.luc.edu/luc_diss/540
  
 
   
 
 
LOYOLA UNIVERSITY CHICAGO 
 
 
MOLECULAR FUNCTIONS OF MLL PHD3 BINDING 
TO ITS LIGANDS CYP33 AND H3K4ME3 
 
 
A DISSERTATION SUBMITTED TO 
THE FACULTY OF THE GRADUATE SCHOOL 
IN CANDIDACY FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
PROGRAM IN MOLECULAR BIOLOGY 
 
BY 
GAYATHREE RAMAN 
CHICAGO, IL 
MAY 2013 
  
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by Gayathree Raman, 2013 
All rights reserved. 
 
  
  
 
   
iii 
 
ACKNOWLEDGEMENTS 
When I started my undergraduate studies, I was just another student with big 
dreams of higher studies. Through the years, several educators helped shape my pursuit 
of higher learning. I want to acknowledge the Loyola University Chicago Graduate 
School and the Molecular Biology Program for providing me the opportunity to undergo 
my graduate studies and helping my dream come true.  
It’s been great learning and conducting doctoral research under the mentorship of 
Manuel O. Diaz, M.D. Dr. Diaz encouraged me to be an independent researcher and at 
the same time provided timely guidance as needed. I am confident that the things I 
learned from Dr. Diaz will help me succeed in my scientific career.  
Ute Osmers, Ph.D., is my go-to person whenever I had questions related to lab 
experiments or techniques or for trouble shooting. I thank her specifically for helping 
with mouse bone marrow isolation and methyl cellulose colony formation assay. Beyond 
all that, she is a good friend who is always there for me. Next, I want to thank and 
acknowledge Wei Wei for helping me understand critical steps in cloning and also for 
helping me with the cloning of MLL-N wt. I want to thank Peter Breslin, Jessica Solanki, 
Steven Poppen , Chris Bien and Carol Bier Lanning, M.D., for their valuable inputs and 
collaborations and for creating a congenial atmosphere in the laboratory.  
  
 
   
iv 
 
I thank my doctoral committee members: Nancy Zeleznik-Le, Ph.D., Richard 
Schultz, Ph.D., Michael J. Thirman, M.D., and Chris Wiethoff, Ph.D., for their valuable 
guidance, motivation and support throughout my graduate research. I also thank all the 
faculty members of Molecular Biology and Bio-chemistry department who provided 
guidance whenever I reached out to them. 
I thank Peggy Richied, Dona Buczek, Lorelei Hacholski and Janet Flores for 
patiently answering countless questions. I also thank Mitchell Denning, Ph.D., for his 
guidance throughout my doctoral program. 
The valuable suggestions provided by the members of the Gene Regulation and 
Epigenetics Group greatly helped me in designing my experiments and also in trouble 
shooting. Specifically, I want to thank Nancy Zeleznik-Le, Ph.D. for being a great role 
model.  I want to thank her lab members Shubin Zhang, M.D and Nick Aichelle for their 
help with retro-virus production, concentration and titration. I thank Jiwang Zhang, M.D 
and Dewen You, Ph.D. for their help with Flow Cytometry experiments. 
Above all, I want to thank my family for being there whenever I needed them. I 
want to extend my sincere and heartfelt thanks to everyone who helped through my 
graduate studies.
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my dad  
  
 
   
vi 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES viii 
LIST OF FIGURES ix 
ABSTRACT xi 
CHAPTER 1: INTRODUCTION 1 
CHAPTER 2: REVIEW OF LITERATURE 8 
Mixed Lineage Leukemia 8 
Domains of MLL Protein 9 
Post Translation Regulation of MLL 15 
Molecular Complexes Containing MLL 15 
Biological Functions of MLL 16 
Transcriptional Targets of MLL 17 
Chromatin Accessibility and Histone Modifications 20 
Cyp33 and H3K4Me3- The Known Ligands of MLL PHD3 22 
Cyp33 and its Functions 24 
JARID1 Histone Demethylases and their Functions 27 
PHD Fingers of Other Chromatin-Associated Proteins 29 
Mutations of PHD Fingers 31 
 
CHAPTER 3: MATERIALS AND METHODS 33 
Cloning Techniques Used In This Study 33 
Generation of MSCV neo MLL-N M1585A and M1606D 36 
Cell culture 37 
Transfection 37 
Retroviral packaging and concentration 38 
  
 
   
vii 
 
Titration of Retrovirus 38 
Isolation of Cells from Mouse Bone Marrow 39 
C-Kit Positive Selection of Mouse Bone Marrow Cells 40 
Retroviral Transduction of C-Kit+ Hematopoietic Progenitors 41 
Liquid Culture of Transduced Hematopoietic Progenitors 41 
Hematopoietic Progenitors Colony Formation Assay 42 
RNA Extraction, DNAseI treatment, cDNA synthesis and qRT-PCR 42 
Chromatin immunoprecipitation (ChIP) followed by quantitative PCR 45 
Western Blot and Immunoprecipitation 49 
Western Blot for MLL-N 50 
Nucleosome pull down assay 51 
 
CHAPTER 4: RESULTS 53 
Aim1: Determine the effect of Cyp33 over expression on transcription of MLL 
target genes. 53 
Aim 2: Determine the significance of MLL PHD3 binding to H3K4Me3 vs Cyp33. 71 
 
CHAPTER 5: DISCUSSION 94 
REFERENCES 110 
VITA 120 
  
  
 
   
viii 
 
LIST OF TABLES 
   
Table                         Page 
1. PHD fingers of Chromatin-Associated Proteins that Bind H3K4Me3 32 
2. Expression Plasmids used in this study 35 
3. Primers Used for Site Directed Mutagenesis 36 
4. Human qRT-PCR Primers 44 
5. Mouse qRT-PCR Primers 45 
6. Antibodies Used in ChIP 47 
7. Human ChIP Primers 48 
8. Mouse ChIP Primers 48 
9. Primary Antibodies Used in Western Blot 50 
  
  
 
   
ix 
 
LIST OF FIGURES 
Figure                                    Page
1. Illustration of domains of MLL wt and MLL fusion proteins. 13 
2. The hetero-dimerization of MLL-N and MLL-C allows the writer and reader to 
be present in the same complex. 14 
3. Ligands of MLL PHD3. 23 
4. Illustration of Protein Domains of Cyp33. 26 
5. JARID1 family histone demethylases. 28 
6. Effect of Cyp33 over expression on transcription of MLL target genes 54 
7. Effect of Cyp33 over expression on histone H3 density at MLL target gene 
promoters 55 
8. Effect of Cyp33 over expression on histone modifications at MLL target gene 
promoters 56 
9. Effect of Cyp33 on the recruitment of H3K4Me3 demethylases JARID1A and 
JARID1B 58 
10. Verification of interaction of Cyp33 and JARID1B in vivo 62 
11. Effect of PPIase activity of Cyp33 on H3K4Me3 and H3K27Ac levels and 
JARID1A and JARID1B recruitment at MLL target gene promoters. 63 
12. Effect of knock down of JARID1B at MLL target genes 67 
13. Effect of knock down of JARID1B and over expression of Cyp33 on the 
transcription of MLL target genes 69 
14. Verification of binding of MLL-N wt to H3K4Me3 nucleosomes in vivo 74 
15. Binding status of M1585A and M1606D to H3K4Me3 nucleosomes in vivo 75 
16. Verification of over expression of MLL-N 77 
  
 
   
x 
 
17. Effect of MLL-N wt and mutants over expression on transcription of MLL 
target genes 80 
18. Effect of MLL-N and mutant over expression on MLL-C recruitment 81 
19. Effect of over expression of MLL-N wt and mutants on histone H3 density 84 
20. Effect of over expression of MLL-N wt and mutants on H3K4Me3 marks 85 
21. Effect of over expression of MLL-N wt and mutants on JARID1B recruitment 86 
22. Verification of over expression of MLL-N wt and mutants in mouse 
hematopoietic progenitors 87 
23. Effect of over expression of MLL-N wt and mutants on MLL target gene 
expression in Ckit+ve mouse hematopoietic progenitors 88 
24. Effect of over expression of MLL-Nwt and mutants on the colony formation 
potential of hematopoietic progenitors 91 
25. Effect of MLL-N wt and mutants over expression on colony formation of 
MLL-AF9 transformed hematopoietic progenitors 92 
26. Putative model for the effect of Cyp33 binding to MLL PHD3 on recruitment 
of MLL-C 104 
27. Model for the function of the MLL PHD3-H3K4Me3 interaction 109 
28. Model for effect of excess of Cyp33 on trimethylation of H3K4 at MLL target 
gene promoters 109 
 
  
 
   
xi 
 
ABSTRACT 
Mixed Lineage Leukemia protein (MLL) is a key epigenetic regulator required for 
proper embryonic development, and fetal and adult hematopoiesis. It is a SET domain 
containing histone methyl transferase that trimethylates histone H3 on lysine 4 
(H3K4Me3), a histone modification that correlates with active transcription. Like many 
chromatin-associated proteins, MLL has multiplePHD fingers. Previous studies from our 
laboratory have shown that the 3rd PHD finger of MLL interacts with the RNA 
Recognition Motif (RRM) of Cyp33. Cyp33 is a Cyclophilin with peptidyl prolyl 
isomerase (PPIase) activity. Over expression of Cyp33 results in transcriptional 
repression of MLL target genes. Thus Cyp33 switches MLL from a transcriptional 
activator to a repressor. In addition to binding to Cyp33, the MLL PHD3 also binds to 
H3K4Me3. Thus MLL is an H3K4Me3 “writer” with an embedded “reader” for the same 
mark. The aim of this study is to determine the biological function of MLL PHD3 
binding to H3K4Me3 or Cyp33.  
The in vitro binding studies performed by our collaborators, Sangho Park and 
John Bushweller, have shown that Cyp33 binding to MLL PHD3 reduces the binding 
affinity of the MLL PHD3 for H3K4Me3 by 5.7 fold. Therefore we sought to determine 
the effect of Cyp33 on H3K4 trimethylation and on transcription of MLL target genes. 
Cyp33 over expression resulted in a decrease in H3K4Me3 and H3Ac marks and increase 
in recruitment of JARID1A and JARID1B, the H3K4 specific demethylases, at the MLL
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target gene promoters in a PPIase dependent manner. Also, shRNA- mediated down 
regulation of JARID1B resulted in transcriptional activation of a sub-set of MLL target 
genes. Thus we have identified JARID1B as transcriptional regulator of MLL target 
genes.             
          To determine the transcriptional outcome of  the MLL PHD3 binding to H3K4Me3 
or Cyp33, we abrogated either H3K4Me3 binding or Cyp33 binding to the MLL PHD3 
by point mutations in the MLL-N coding sequence and assessed the effect of expressing 
the mutant proteins on MLL target gene expression. Over expressing wild type (wt) 
MLL-N resulted in increased expression of a sub-set of MLL target genes, increased 
recruitment of MLL-C and increased H3K4Me3 at MLL target gene promoters. 
Abrogating Cyp33 binding resulted in transcriptional activation of MLL target genes, 
however the effect was similar to that of wt MLL-N over expression. Unlike MLL-N wt , 
abrogation of H3K4Me3 binding to the MLL PHD3 did not result in transcriptional 
activation of MLL target genes, did not show an increase in MLL-C recruitment and did 
not increase H3K4Me3 levels. Also, abrogation of MLL PHD3 binding to H3K4Me3 
resulted in decreased expansion of mouse hematopoietic progenitors in a methyl cellulose 
colony formation assay when compared to wt MLL-N. This indicates that the MLL 
PHD3 binding to H3K4Me3 contributes to the transcriptional activation of MLL target 
genes in hematopoietic progenitors. Thus, MLL PHD3 binding to H3K4Me3, contributes 
to the expansion of hematopoietic progenitors, demonstrating the biological significance. 
Taken together, the transcriptional outcome of MLL target genes is influenced by Cyp33 
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and H3K4Me3, the ligands of MLL PHD3. Therefore the MLL PHD3 serves as a ligand 
regulated molecular switch influencing the transcription of MLL target genes.  
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CHAPTER 1 
INTRODUCTION 
The MLL protein is a Trithorax group transcriptional regulator that is 
evolutionarily conserved throughout metazoans 
1
. It belongs to the MLL family of SET 
domain containing histone methyl transferases which methylate histone H3 on lysine 4 
2–
5
. The H3K4Me3 mark at gene promoters is associated with active transcription. In 
addition to its histone methyl transferase activity, MLL is a multi-domain containing 
protein. The domains of MLL allow it to associate with DNA, other chromatin regulators 
and histone modifiers, making it a versatile and a key epigenetic regulator.  
MLL (MLL wt) is required for fetal and adult hematopoiesis and for embryonic 
development 
6,7
. It is required for the maintenance of H3K4Me3 marks at Hox gene 
promoters 
3
. Hox genes are a cluster of conserved, homeo-box containing transcription 
factors, responsible for the proper segmental identity during embryonic development and 
for the maintenance of tissue-specific developmental programs in adults 
8
. In addition to 
its known role in embryonic development and hematopoiesis, MLL is also a cell cycle 
regulator. Cell cycle promoters of E2F target genes and cell cycle inhibitors like 
CDKN1A and CDKN1B are known targets of MLL 
9–11
.  
            Chromosomal rearrangements of the MLL gene are a frequent phenomenon in 
mixed lineage leukemia, hence the name MLL for the gene and protein 
12,13
.The MLL 
fusion proteins constitutively activate the transcription of a sub-set of MLL target genes  
 2 
 
 
 
resulting in increased self-renewal of hematopoietic progenitors, keeping them in an 
undifferentiated state and eventually leading to leukemogenesis 
14–16
. MLL rearranged 
leukemia are aggressive, are often associated with poor prognosis and the available 
treatments do not increase the survival of the patient significantly 
17–19
. In MLL 
rearranged leukemia, only one of the MLL alleles is rearranged, the other allele is intact, 
and recent studies have demonstrated that MLL fusion protein requires the co-expression 
of  the wild type MLL (MLL wt) for MLL fusion mediated transformation and 
leukemogenesis 
20
. To design successful treatments for MLL rearranged leukemia one 
must know the relevant functions and contribution of MLL wt in leukemogenesis. MLL 
fusion proteins lacks PHD fingers, a bromo-domain, an activation domain and the SET 
domain, but retain the N-terminal region of MLL through the repression domain 
21,22
 . 
Studies from our laboratory (Chen et al., 2008) and from another group (Muntean et al., 
2008) have shown that inclusion of the MLL PHD3 in a MLL fusion protein blocks MLL 
fusion mediated transformation of hematopoietic progenitors. Our present study focuses 
on understanding the role of MLL PHD3, and its ligands, in transcriptional regulation of 
MLL target genes.  
           Previous studies from our lab have shown that the RRM (RNA Recognition Motif) 
domain of Cyp33 is a ligand for MLL PHD3 
23
. Over expression of Cyp33 causes 
transcriptional repression of MLL target genes. Cyp33 belongs to the cyclophilin family 
of proteins. The RRM of Cyp33 binds AU rich RNA, is known to be present in 
spliceosomes and is involved in pre- mRNA splicing 
24
. The cyclophilin domain of 
Cyp33 possesses Peptidyl Prolyl Isomerase (PPIase) activity which facilitates the cis-
trans conformation  change of prolyl  peptide bonds 
25
. 
23
  Double point mutations in the 
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Cyclophilin domain of Cyp33, R191A and F196A resulted in at least 99% reduction in 
the cis-trans proline isomerization (Wei, Breslin, Schultz, and Diaz, unpublished). The 
PPIase activity of Cyp33 is critical for the transcriptional repression of MLL target genes 
26
. 
       Over expression of Cyp33 augmented the recruitment of  the transcriptional co-
repressors HDAC1 and Bmi-1 
27
. MLL fusions lack PHD3 and are resistant to Cyp33 
mediated repression of MLL target genes. The inclusion of the MLL PHD3 in MLL-ENL 
fusion proteins enabled the fusion proteins to interact with Cyp33 and recruit HDAC1 to 
the repression domain of MLL resulting in decreased expression of MLL target genes. As 
a consequence, the MLL fusion mediated transformation of mouse hematopoietic 
progenitors was blocked by inclusion of MLL PHD3 in MLLfusion
28
. 
Another ligand that binds MLL PHD3 is H3K4Me3. Recently, we and others have 
reported that the MLL PHD3 present in MLL-N, binds to H3K4Me3 
26,29,30
. The MLL 
PHD3 is a small domain of 60 amino acids. The Cyp33 binding site and H3K4Me3 
binding sites are very close to each other. Hence binding of one ligand may affect the 
binding of the other. Furthermore, results from in vitro binding studies performed by our 
collaborators (Park and Bushweller) have revealed that the presence of Cyp33 increased 
the Kd (dissociation constant) for MLL PHD3 binding to H3K4Me3 by 5.7 fold. Thus 
Cyp33 reduces the affinity of MLL PHD3 for H3K4Me3 
26
. If this is true in vivo, then an 
excess of Cyp33 would be predicted to affect the binding of MLL PHD3 to H3K4Me3. 
As a consequence, the H3K4Me3 marks would be exposed to histone demethylases 
resulting in demethylation of H3K4Me3 at MLL target genes promoters.  The presence of 
the H3K4Me3 mark at MLL target gene promoters is associated with open chromatin and 
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transcriptional activation.  Therefore a decrease in H3K4Me3 would result in decreased 
target gene expression. This hypothesis was tested by studying the effect of Cyp33 over 
expression on H3K4 trimethylation at MLL target genes. Cyp33 over expression results 
in increased recruitment of JARID1 histone demethylases and a corresponding decrease 
in H3K4Me3 levels at MLL target gene promoters. Thus this study has identified another 
mechanism of Cyp33-mediated transcriptional repression of MLL target genes.  
JARID1 family proteins are histone H3K4Me3 specific demethylases 
31–34
. 
Among the JARID1 family proteins, JARID1A and JARID1B have three PHD fingers. 
The PHD3 of JARID1A and JARID1B are known to bind to H3K4Me3
35
. They are 
H3K4Me3 “erasers” with an embedded “reader” for H3K4Me3 and therefore, can bind to 
H3K4Me3 and demethylate H3K4Me3 in adjacent histones or nucleosomes.   
MLL is a “writer” with an embedded “reader”. Nevertheless, the writer and reader 
functions are imparted by two separate protein fragments of MLL. The MLL protein is 
proteolytically cleaved into an N-terminal (MLL-N) and a C-terminal (MLL-C) 
fragments by the protease TASPASE-1 
36. The PHD3 that binds to H3K4Me3 (“reader”) 
is present on MLL-N, while the SET domain (“writer”) is present on MLL-C. MLL-N 
and MLL-C interact directly through their FYRN and FYRC domains, and this 
interaction protects MLL-N from degradation by the E3 ubiquitin ligase SCF 
Skp 37
. The 
nuclear localization signal in MLL-N is required for nuclear translocation of MLL-C. 
Thus the two different fragments require each other for  functional holo-complex 
formation at the MLL target gene promoters 
38
.  Furthermore, the MLL-N and MLL-C 
interaction brings the reader and writer of H3K4Me3 together in the same complex. 
Hence we proposed that the MLL PHD3 binding to H3K4Me3 may help MLL-C to 
 5 
 
 
 
methylate histone H3K4 on adjacent nucleosomes and also protect the methylated lysine 
4 from histone demethylases, resulting in transcriptional activation of MLL target genes.  
Additionally, the activation domain of the MLL-C associates with histone acetyl 
transferases (HATs) like CBP and p300 
39
. The acetylation of histones opens the 
chromatin and allows the DNA to be accessible to transcription factors and the basal 
transcription machinery. The acetylation of histones is associated with transcriptional 
activation. MLL PHD3 binding to Cyp33 enhances the recruitment of transcriptional 
repressors like HDAC1 (Histone Deacetylase) and Bmi-1 leading to transcriptional 
repression of MLL target genes. For all the above mentioned reasons, we hypothesized 
that the MLL PHD3 binding to H3K4Me3 versus Cyp33 may have opposite effects on 
the transcriptional outcome for MLL target genes. Therefore, we wanted to determine the 
effect of abrogation of MLL PHD3 binding to H3K4Me3 or to Cyp33 on the transcription 
of MLL target genes in mouse embryonic fibroblasts (MEFs) and in primary mouse 
hematopoietic progenitors. 
The point mutations that disrupt MLL PHD3 binding to H3K4Me3 or Cyp33 were 
introduced in the PHD3 encoding region of MLL-N. MLL-N wt or its mutants were over 
expressed in MEFs or in mouse hematopoietic progenitors and the effects on transcription 
of MLL target genes and on colony formation by hematopoietic progenitors was studied. 
Interestingly, over expression of MLL-N wt without over expressing the MLL-C resulted  
in increased H3K4Me3 marks, increased  recruitment of MLL-C and increased 
transcriptional activation of a sub-set of MLL target genes. On the other hand, abrogation 
of MLL PHD3 binding to H3K4Me3 resulted in decreased H3K4Me3 marks and MLL-C 
recruitment at MLL target gene promoters, as well as decreased expression of a sub-set of 
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MLL target genes. More importantly, abrogation of MLL PHD3 binding to H3K4Me3 
resulted in a drastic decrease in colony formation of primary mouse hematopoietic 
progenitors indicating a defect in their proliferation. The abrogation of MLL PHD3 
binding to Cyp33 resulted in transcriptional activation of a sub-set of MLL target genes; 
however, the effects were similar to that of MLL-N wt over expression.  
As mentioned earlier, recent studies have implicated the Mll wt allele in 
leukemogenesis and transformation of Mll fusion mediated leukemia. Milne et al., have 
shown that the MLL fusion protein binds to the Hoxa9 promoter only when the promoter 
is already bound by the MLL wt protein. They identified the repression domain and PHD 
fingers as the minimal regions in MLL wt that contributes to the targeting of the MLL 
fusion to the Hoxa9 promoter. Mutation of the PAF binding site in the repression domain 
and the H3K4Me3 binding site in the MLL PHD3 affected the MLL fusion’s ability to 
bind to its target promoters
40
. Results from this study show that abrogating H3K4Me3 
binding or Cyp33 binding to MLL PHD3 did not have any effect on MLL-AF9 mediated 
transformation of hematopoietic progenitors in a serial plating methyl cellulose colony 
formation assay. However, the effect of abrogation of H3K4Me3 binding of the MLL 
PHD3 on cell transformation by other MLL fusions has yet to be determined. 
In conclusion, MLL PHD3 binding to H3K4Me3 contributes to H3K4 
trimethylation, followed by transcriptional activation of a sub-set of MLL target genes 
and colony formation by hematopoietic progenitors. Additionally, we have identified a 
link between the JARID1 histone demethylases and Cyp33 mediated transcriptional 
repression of MLL target genes. Thus, the ligands of the MLL PHD3 influence the 
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transcription of MLL target genes and act as a molecular switch for transcriptional 
regulation of MLL target genes.  
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CHAPTER 2 
REVIEW OF LITERATURE 
Mixed Lineage Leukemia 
Mixed Lineage leukemia is a distinct molecular sub-type of acute leukemia that 
occurs as a result of the chromosomal rearrangement of the 11q23 region. In these MLL 
rearrangements, the 11q23 chromosomal breakpoint region falls within the MLL gene and 
since this cytogenetic abnormality is found in both acute myeloid or acute lymphoid 
leukemia, often with lineage infidelity (expression of some markers of the opposite 
lineage), the gene is named  after the disease 
12
. The translocation of MLL with another 
gene results in an in-frame fusion gene that encodes for the leukemogenic MLL fusion 
protein. So far, there are 100 different recurrent MLL translocations reported, with at least 
60 different partner genes 
41
. MLL-rearranged leukemia accounts for 70% of all ALL and 
35-50% of all AML in infants. In older children and adults it accounts for about 10% of 
all leukemia. Patients with MLL- rearranged leukemia show poor prognosis. The more 
common fusion partners of MLL are AF4, AF9, ENL, AF10, AF6, ELL, AF17, and 
SEPT6 which altogether account for 90% of MLL-rearranged leukemia 
42
.  
Besides chromosomal rearrangement, gene amplification and partial tandem 
duplication (PTD) of MLL are other mechanisms of deregulation of MLL that occur 
frequently in acute leukemia. About 3- 20 copies of the entire MLL gene are found in the 
leukemic cells of older patients with acute leukemia or myelodysplatic syndrome 
43
. The 
 9 
 
 
 
exons 11-5 or 12-5 of the MLL gene are duplicated in the PTD of MLL. MLL PTD retains 
the TASPASE1 cleavage site and C-terminal histone methyl transferase activity. About 
4-7% of AML patients have MLL PTD 
44
. 
Domains of MLL Protein 
MLL is a very large, 431 kDa protein with many different identified domains that 
mediate protein-DNA, protein-protein, or protein-RNA interactions. The MLL protein is 
proteolytically cleaved into an N- (MLL-N) and a C-terminal (MLL-C) fragment by the 
protease TASPASE1 
36
. The MLL-N fragment has a Menin binding region, 3 AT hooks, 
a repression domain, 4 PHD fingers, an atypical bromo domain and a FYRN 
(Phenylalanine and Tyrosine Rich N-terminus) domain. The MLL-C fragment has the 
transcriptional activation domain, a FYRC (Phenylalanine and Tyrosine Rich C-terminus 
domain). The chromosomal break point region is just before PHD1
12
. Hence the fusion 
protein contains a portion of MLL N-terminus through the repression domain fused in-
frame with a C- terminal partner protein fragment. The rest of the N-terminus (from the 
PHD finger region to the TASPASE1 cleavage site) and the whole of MLL-C fragment is 
deleted in the MLL fusion protein as shown in Figure 1. Nevertheless, the deleted regions 
are frequently, but not always, represented in the reciprocal translocation product. 
The first 43 amino acids of the N-terminus of MLL contains the Menin binding 
site
45
. Menin enhances the localization of MLL to its target promoters, is required for 
MLL’s histone methyl transferase activity and thus for the MLL target gene expression 
46,47
. Furthermore, Menin brings in other oncogenic factors like LEDGF and c-Myb to 
MLL and is essential for MLL fusion mediated leukemogenesis 
48,49
.  
 10 
 
 
 
The MLL AT hooks, similar to the ones present in the HMG group proteins, bind 
AT-rich DNA sequences. However, the AT hooks of MLL do not recognize DNA in a 
sequence specific manner. Instead, they recognize and  bind to cruciform DNA structures 
21
.  This region of MLL also is also a mediator of an interaction with the SET onco- 
protein, and with GADD34 
50,51
. The first 1,100 amino acids of MLL-N  are required for 
MLL localization in a punctate distribution in the cell nucleus. Specifically, the SNL1 
and SNL2 regions present in the N-terminal region of MLL contribute to the sub-nuclear 
localization of MLL 
52
. 
The repression domain of MLL recruits transcriptional co-repressors like 
HDAC1, hPC2, Bmi-1 and CtBP 
27
.  Part of the MLL repression domain encodes the 
CXXC domain which binds to non-methylated CpG on the DNA 
53
. Through this 
property, MLL protects CpG dinucleotide sequences from DNA methylation 
54
. Recent 
studies have shown that the repression domain of MLL recruits PAF1, a member of the 
PAF-C transcriptional elongation complex, to MLL target gene promoters and is required 
for the MLL fusion mediated leukemogenesis and transformation 
55
. 
There are three tandem PHD fingers and an atypical extended PHD finger in 
MLL. This region of MLL is highly conserved from Drosophila to humans. The PHD 
fingers of MLL homodimerize; however, the significance of homo-dimerization is yet to 
be determined 
23
. The first and fourth PHD fingers of MLL contribute to the interaction 
between the MLL-N and MLL-C fragments 
38
. A recent study has shown that the second 
PHD finger of MLL has an E3 ligase activity and requires the E2 ubiquitin conjugating 
enzyme CDC34 for its activity. Histones H3 and H4 were identified substrates of 
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ubiquitination in vitro. The PHD2 E3 ligase activity negatively regulates MLL target 
gene expression 
56
. 
The third PHD finger of MLL is the region of interest of this study. Yeast two 
hybrid studies performed in our laboratory identified Cyp33 as a ligand for the MLL 
PHD3. Cyp33 over expression augmented the recruitment of the transcriptional 
repressors like HDAC1 and Bmi-1, to the repression domain and resulted in 
transcriptional repression of MLL target genes 
23
. The PHD3 of Trithorax (TRX), the 
Drosophila homologue of MLL, also binds to Drosophila Cyp33 
57
. All the PHD fingers 
are deleted in leukemogenic MLL fusions. The insertion of  the MLL PHD3 in a MLL-
ENL fusion protein, enabled the fusion protein to interact with Cyp33 and recruit HDAC 
to the repression domain of MLL,  resulting in decreased expression of MLL target genes 
28
. Thus , the wild type MLL responds to transcriptional activation or transcription 
repression cues and switches on or off target genes expression. But the MLL fusions are 
resistant to the mechanisms of transcription repression and constitutively activate the 
target genes. Similar to other PHD finger containing chromatin-associated proteins, 
PHD3 of MLL binds to trimethylated H3K4 
26,29,30
. The binding of MLL PHD3 may 
contribute to the transcriptional activation of MLL target genes. The MLL fusion protein 
binds to the target promoters that are already bound by wild type MLL. MLL PHD3 
binding to H3K4Me3 and PAF1 binding to the repression domain cooperate to recruit 
MLL wt to the target promoter 
40
.  
A short amino acid sequence between the PHD4 and the bromo-domain of MLL 
is required for interaction with HCF1, a cofactor of E2F1. This interaction recruits MLL 
to E2F responsive promoters 
9
. The bromo-domain of MLL is an atypical one and does 
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not bind acetylated lysine, however its interaction with the MLL PHD3 increases the 
affinity of the latter for H3K4Me3
29
. The FYRN domain of MLL is a phenyl alanine and 
tyrosine rich region in the N-terminus which interacts with the FYRC region present in 
the C-terminus, thus tethering the MLL-N and MLL-C fragments together (Figure 2)
36
. 
The transcriptional activation domain of MLL-C binds to histone acetyl 
transferases like p300 and CBP 
39
. The region adjacent to the activation domain interacts 
with the H4K16 acetyl transferase MOF and this interaction contributes to the 
transcriptional activation of HOX genes 
58
. The SET domain of MLL is the catalytic 
domain that possesses the histone methyl transferase activity. The SET domain requires 
other core components of the COMPASS-like complex, RbBP5, ASH2L, WDR5 and 
DPY-30 to trimethylate histone H3 on lysine 4 
59
.  
The SET domain has been reported to play a role in homo-dimerization and single 
stranded DNA and RNA binding 
60,61
. The domains of MLL act as platforms for both 
homo and hetero-molecular interactions empowering MLL to be a key epigenetic 
regulator. 
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MLL wt is proteolytically cleaved into MLL-N and MLL-C fragments by 
TASPASE1. Both MLL wt and the fusion have AT hooks, the Sub-Nuclear 
Localization (SNL) 1 and 2, repression domain (RD). The chromosomal break point 
region is just before or within the PHD1. Hence the region including the PHD fingers, 
the bromo-domain, the FYRN domain, the Activation domain (AD) and the SET 
domain is not present in the fusion proteins. MLL wt is a writer with an embedded 
reader. The SET domain is a histone methyl transferase that trimethylates histone H3 
on lysine 4. The PHD3 is the reader that recognizes H3K4Me3 marks.   
Figure 1: Illustration of domains of MLL wt and MLL fusion proteins. 
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Figure 2: The hetero-dimerization of MLL-N and MLL-C allows the writer and 
reader to be present in the same complex. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
MLL is a writer with an embedded reader for H3K4Me3. The SET domain of MLL is 
a histone methyl transferase that trimethylates histone H3 on lysine 4, hence it is a 
writer. The PHD3 of MLL binds to H3K4ME3; hence it is a reader of H3K4Me3. 
Though the writer and reader functions are present in the same protein, due to 
proteolytic cleavage by TASPASE1 they are separated in two different polypeptides. 
The proteolytic cleavage of MLL by TASPASE1, results in a 320 kDa MLL-N 
fragment and a 180 kDa MLL-C fragment. The MLL-N and MLL-C interact through 
their FYRN and FYRC domains. This interaction protects MLL-N from degradation 
and also is required for nuclear localization of MLL-C. Also, allows the writer and 
reader to be present in the same complex. 
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Post Translational Regulation of MLL 
MLL is proteolytically cleaved by TASPASE1 and this cleavage is essential for 
the histone methyl transferase activity of MLL and transcription regulation of MLL target 
genes. The nuclear localization signal in MLL-N is required for nuclear translocation of 
MLL-C. MLL-N is targeted for degradation during the S and M phases of the cell cycle 
by SCF 
Skp 
and APC 
Cdc20 
E3
 
ligases 
37
. The interaction of MLL-N and MLL-C stabilizes 
MLL-N and protects it from degradation. The MLL-C protein that is not bound to MLL-
N cannot enter the nucleus and is targeted for proteasome-mediated degradation in the 
cytoplasm. Thus the two fragments require each other for formation of the functional 
enzymatically active holo-complex at target gene promoters 
38
. Furthermore, MLL-N and 
MLL-C interaction brings the reader and writer of H3K4Me3 together in the same 
complex as shown in Figure 2. MLL fusions do not have the TASPASE1 cleavage site; 
hence they are resistant to cell cycle specific degradation. MLL is phosphorylated at Ser 
516  by ATR. This phosphorylation event is a response to DNA damage and is required 
for correct execution of the S-phase check point. Phosphorylation at Ser 516 disrupts the 
interaction with SCF 
Skp
 and protects MLL from degradation. The accumulated MLL then 
methylates the histone H3K4 at the late replicating origins, and inhibits CDC45 loading, 
thus delaying DNA replication. The MLL fusion gets phosphorylated at Ser 516 but lacks 
the SET domain, hence resulting in a dysregulated S phase check point 
62
. 
Molecular Complexes Containing MLL 
The very first immunoaffinity purification of MLL complex was performed by 
Nakamura et al. That study identified MLL is present in complex with 28 other proteins. 
Other notable proteins of this complex are global transcription regulators that belong to 
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the core transcriptional machinery like TFIID and TBP; ATP-dependent nucleosome 
remodeling proteins like SWI/SNF, NuRD (HDAC), hSNF2H and Sin3A (HDAC); and 
other core components of the yeast Set1 histone methyl transferase complex like RbBP5 
and WDR5. Though MLL is generally considered as the transcriptional activator, in this 
complex it was present along with transcriptional repressors like HDAC. More 
interestingly, except for MLL, there are no other Trithorax group proteins present in the 
complex.  
Yokoyama et al. biochemically purified MLL along with the core components of 
SET1 like, complex. The proteins present in the complex are RbBP5, ASH2L, WDR5 
and DPY-30. The SET domain of MLL is not intrinsically active for the H3K4 methyl 
transferase activity. These proteins are required for the substrate recognition and 
enzymatic activity of the MLL SET domain and thus for the transcriptional activation of 
MLL target genes. Additionally, this protein also contains HCF1 and Menin. In contrast 
to the super-complex identified by Nakamura, this 1MDa complex is much smaller in 
size and is made exclusively of transcriptional activators 
59
.   
Biological Functions of MLL 
 MLL belongs to the Trithorax group (trx-G) proteins that are positive 
transcriptional regulators, which antagonize the function of Polycomb (PcG) mediated 
transcriptional repressors 
63
. The trx and Pc-G  proteins, which maintain the identity of 
cells by keeping the target genes active or silent respectively are key components of the 
epigenetic mechanisms that dictate cell fate determination 
64
. The TRX mutants in 
Drosophila show anterior or posterior segmental transformations
65
. Yu et al. generated 
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Mll hypomorph mice by inserting promoter less lacZ in the third exon of Mll. The 
homozygous deletion of Mll (Mll-/-) is embryonically lethal at around day 10.5. Hox 
genes are expressed in Mll-/- mice until day 9.5, but their expression was not maintained 
any further, showing that Mll  is required for the maintenance rather than initiation of 
Hox gene expression. Mice heterozygous for Mll (Mll+/-) were smaller in size, anemic 
and had defects in the axial skeleton, disordered segmental identities of cervical, thoracic 
and lumbar regions; highlighting the importance of MLL in development and 
hematopoiesis 
8
. Mice with homozygous deletion of the SET domain of Mll also have 
altered body segments, decreased H3K4 mono methylation and decreased Hox gene 
expression 
66
. The altered segment phenotypes are features of homeotic transformation, 
mirroring the phenotype of Trx mutations in Drosophila. Furthermore in mammals, Mll is 
required for normal hematopoiesis, skeletal and neural development. Mll-/- yolk sac and 
fetal liver have reduced cellularity and the hematopoietic progenitors from fetal livers 
show decreased expansion in methyl-cellulose colony formation assays 
6
. This showed 
that Mll is critically required for fetal hematopoiesis, specifically required for the fetal 
HSC self-renewal. Using a conditional knock out of Mll, McMahon et al. showed that 
Mll is also required for self-renewal of HSCs postnatally 
67
.   
Transcriptional Targets of MLL 
 Genome wide MLL occupancy and in vivo mouse studies and have been 
undertaken to identify the targets of MLL. Several studies have shown that MLL binds to 
a specific set of target gene promoters and through its intrinsic histone methyl transferase 
activity; and associated acetyl transferase activities activates the transcription of these 
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target genes. However, genome wide ChIP on chip for human MLL performed by 
Guenther et al. showed that 90% of RNA PolII bound promoters of actively transcribing 
genes were also bound by MLL. Furthermore 92% of MLL-bound promoters showed 
enrichment for H3K4Me3 suggesting a global role for the histone methyl transferase 
function of MLL in transcription. Interestingly, the findings from this study showed MLL 
occupancy and H3K4 trimethylation at HOX genes like HOXA7, HOXA9, HOXA10, 
HOXA11 and HOXA13 was not just limited to the transcription start site and 5’ region of 
the gene. Instead the chromatin was extensively occupied by MLL both upstream and 
downstream of the genes, and this binding correlated with active transcription of the 
genes. This was also shown for another MLL target gene Meis1 
68
. Milne et al. showed 
that the C-terminus of MLL interacts with the Ser5 phosphorylated RNA polII CTD 
suggesting a global role for MLL in transcription. However, they also showed that MLL 
occupied only a subset of actively transcribing genes. ChIP performed for Mll and Ser5 
phosphorylated CTD in MEFs and showed that they co-localized at Mll target genes like 
Hoxa9 and Hoxc8 
69
.  
 In striking contrast to Guenther et al.’s finding, a genome wide ChIP on chip 
performed by Wang et al. in Mll +/+ and Mll-/- MEF showed that only 5% of promoters 
showed a Mll-dependency for H3K4 trimethylation. In agreement with a majority of 
studies in the MLL field, this study also identified a sub-set of Hox genes like Hoxc8, 
Hoxc9 and Hoxc6 as Hoxc5, Hoxb4, Hoxb6, Hoxb10, Hoxa6, Hoxa7, and Hoxa9 as key 
MLL target genes. Moreover, MLL and MLL4 (also called MLL2) show some level of 
redundancy in regulating the transcription of their targets. Additionally, this study also 
identified that a major fraction of the MLL target genes are transcription factors and also 
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identified a couple of novel targets in the Wnt signaling pathway  which in turn regulate 
the transcription of Hox genes 
70
.  
 Though the genome wide studies for the target genes of MLL show some 
contradictions, the in vivo studies from Mll mutant or knockout mice studies have clearly 
demonstrated Hox-specific phenotypes. Hox genes code for evolutionarily conserved 
homeo-domain containing transcription factors. There are 39 Hox genes in mammals, 
arranged in four clusters (A to D) present in four different chromosomes. They are 
required for positional identity of body segments along the anterio-posterior axis of the 
body 
71
. Hence they have a pivotal role in fetal development and embryogenesis. Hoxa5, 
Hoxa7, Hoxa9, Hoxa10, Hoxb3, Hoxb6 and Hoxc8 are the Hox genes that have been 
shown to be critical for hematopoietic stem cell (HSC) self-renewal 
72
. Though many Hox 
genes are required for normal hematopoiesis, a few Hox genes like Hoxa9, Hoxa7 and 
Hoxa10 are over expressed in MLL-rearranged leukemia and  are necessary for the 
leukemic transformation of hematopoietic progenitors.  
 Meis1 is another MLL target gene that encodes for a TALE (Three Amino acid 
Loop Extension) sub-type of homeo-box containing transcription factor 
68,69
. Unlike Hox 
genes, the Meis family genes are non-clustered. Meis1 collaborates with Hox9-13 to bind 
DNA 
14
. It is over expressed along with Hoxa9 in MLL-rearranged leukemia and co-
operates with Hoxa9 in leukemic transformation of hematopoietic progenitors 
15
.  
 RUNX1 (AML1) is another gene that is frequently rearranged in AML leukemia. 
Like MLL, the RUNX1 protein is also required for normal hematopoiesis. Recently 
Huang et al., identified that an MLL interaction with the N-terminus of RUNX1 protects 
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RUNX1 from ubiquitin mediated proteosomal degradation. Moreover, MLL is required 
for maintenance of H3K4 trimethylation at the promoter of RUNX1 target genes like 
PU.1
73
. Besides Hox genes, cell cycle regulators like Myc and E2F1 target genes are also 
targets of MLL. Using a Taspase1-/- mice, Hsieh et al. demonstrated that proteolysis of 
MLL is required for transcriptional regulation of its targets. Taspase1-/- mice showed 
homeotic phenotype similar to Mll mutant mice, in addition, the Taspase1 null mice were 
smaller in size. Furthermore, this study identified E2F target genes as transcriptional 
targets of MLL, highlighting a role for MLL in cell cycle regulation 
74
. MLL is also a 
transcriptional regulator of cell cycle inhibitors like Cdkn1a and Cdkn1b 
10
,
11
. 
Chromatin Accessibility and Histone Modifications 
The human genome is made of more than 3 billion base pairs. To fit into a cell 
nucleus that is about 2µm in diameter, DNA has to be compacted at least 10,000 fold. 
This is made possible by wrapping of DNA around histones
75
.  An histone octamer made 
from four different histones: H3, H4, H2A and H2B. About 146 bp of DNA are wrapped 
around a histone octamer forming a mononucleosome. Each mono nucleosome is 
connected to another by a linker histone, this arrangement or packaging fashion is 
referred to as beads on a string model which further coil helically to form a higher order 
solenoid in which the diameter of the chromatin fiber is 30 nm 
76,77
. Though histones are 
very useful in compaction of DNA, they limit the accessibility of DNA for various DNA-
templated cellular processes like transcription, DNA replication, DNA damage-response 
repair, recombination etc 
78,79
. Chromatin associated proteins are key modulators of DNA 
accessibility. Post translational modifications of histone tails, exchange of core histones 
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for histone variants, sliding of nucleosomes by nucleosome remodeling complexes are the 
mechanisms that regulate the accessibility of DNA to regulatory proteins.  
A portion of the amino terminal region of core histone proteins protrudes from the 
nucleosome, and is accessible to histone modifying enzymes. Post translational histone 
modifications act as docking sites for proteins that recognize the histone code and recruit 
other effector proteins 
80
. The enzymes that post translationally modify the histones are 
referred to as writers. The proteins that recognize the modifications are referred to as 
readers. The proteins that remove the modifications are referred to as erasers. The basic 
amino acids like lysine and arginine in histones can be methylated. Additionally, lysines 
can be acetylated or ubiquitinated. The serines and threonines can be phosphorylated.  
The effect of histone modification on transcription is very well studied. The 
transcriptional outcome depends on the amino acid modified, the histone tail the amino 
acid is present in (H3, H4, H2A and H2B), and the nature of the modification 
81
. 
Acetylation of lysines in histones is considered as a transcriptional activation mark  
82
.  
HATs like p300, CBP, and  MOF are the enzymes that acetylate the lysines on histones, 
and the mark is removed by histone deacetylases ( HDACs Class I, II and III) 
83,84
.  
Acetylated lysines are recognized by bromo-domain containing proteins
85
. 
 Histone methyl transferases; mono-, di- or trimethylate lysines on histones and 
have a SET (an acronym framed from the histone methyl transferases in Drosophila 
Su(Var)39, Enhancer of Zeste and Trithorax) domain as the catalytic domain. Some 
lysine methylation like H3K4Me3 is correlated with active transcription, whereas 
H3K9Me3 and H3K27Me3 are correlated with gene repression. The chromodomain, 
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Tudor domain, WD-40 repeat and PHD fingers recognize methylated lysines 
85
. The Set1 
enzyme found in yeast mono-, di-, and tri-methylates histone H3K4. SET1A and SET1B 
MLL, MLL2, MLL3, and MLL4 are the H3K4 specific histone methyl transferases in 
mammals
4
. The mammalian histone demethylase that demethylates mono- and di- 
methylated H3K4 is LSD1.The mammalian demethylases JARID1A, JARID1B, 
JARID1C and JARID1D demethylates mono-, di-, and tri-methyl histone H3K4 
86
.  
Cyp33 and H3K4Me3- The Known Ligands of MLL PHD3 
The known ligands of MLL PHD3 are Cyp33 and H3K4Me3 (Figure 3A). 
Structural and NMR studies of MLL PHD3 binding to Cyp33 or H3K4Me3 were 
characterized by three different groups 
26,29,30,87
. The in vitro binding studies from our 
collaborators Sangho Park and John Bushweller and from another group,  have shown 
that Cyp33 has a higher binding affinity for MLL PHD3 than H3K4Me3 
26,30,87
. 
Isothermal calorimetry studies show that the MLL PHD3 binds to Cyp33 RRM with a 
kDa of 14.7 µM while the kDa for H3K4Me3 is 30.9 µM. Cyp33 and H3K4Me3 bind to 
two distinct surfaces of the MLL PHD3 but they are very close to each other. The effect 
of RRM of the Cyp33 on MLL PHD3-H3K4Me3 complex formation and vice versa 
shows that the interactions are mutually inhibitory 
26
. The hydrophobic residues present 
on the α1 and α2 helices and on the loop 4 of the MLL PHD3, projects into the groove of 
β sheet of the Cyp33 RRM. This interaction is primarily mediated by hydrophobic 
residues V1617, Y1619, M1606, I1609 and L1610 in the MLL PHD3 and V7, Q36, F51, 
D53 and A82 in the Cyp33 RRM as shown in Figure 3B. 
 
 23 
 
 
 
 
 
Figure 3: Ligands of MLL PHD3. 
 
A, Schematic of MLL PHD3 binding to Cyp33 or H3K4Me3; B, A ribbon representation 
of the interaction of MLL PHD3 (blue) and Cyp33 RRM (magenta). The residues that are 
involved in the interaction in MLL PHD3 are in green and in Cyp33 RRM are in yellow. 
C, Crystal structure showing the hydrogen bonds between MLL PHD3 (blue) and bound 
H3K4Me3 peptide (yellow). This figure is from Z.Wang et al. Cell, 2010. 
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The high affinity interaction of the MLL PHD3 with the RRM of Cyp33 is inhibited by 
linking the MLL PHD3 to bromo-domain of MLL. However, this inhibition is overcome 
by adding the PPIase domain of Cyp33. The PPIase activity of Cyp33 targets the P1629 
present in the linker region between the MLL PHD3 and the bromo-domain resulting in a 
conformational change that allows of the binding of MLL PHD3 to the RRM of Cyp33 
29
. 
The above mentioned finding is from in vitro binding studies. The importance of 
isomerization of P1629 on Cyp33 binding is yet to be demonstrated in a cellular system. 
Similar to other PHD fingers that bind H3K4Me3, the MLL PHD3 also forms an 
aromatic cage that act as a binding module for the trimethyl ammonium group of K4Me3. 
The interaction is primarily mediated by Y1576, Y 1581, M1585 and W 1594 in the MLL 
PHD3. The binding of the MLL PHD3 to H3K4Me3 results in a conformational change 
in the loop segment between Y15756 to M1585A resulting in a conformational change 
that burries the methyl side chain of H3K4 in the aromatic cage. Moreover Wang et al. 
have shown that the bromo domain of MLL also contributes to the recognition of 
H3K4Me3 
29
. The MLL PHD3 interacts with the extended helix of the bromo-domain of 
MLL. In the absence of the interaction between MLL PHD3 and bromo domain only a 
partial aromatic cage is formed.  The binding of the MLL PHD3 to H3K4Me3 contributes 
to the transcriptional activation of MLL target genes however the biological significance 
of this binding has yet to be determined.  
Cyp33 and its Functions 
 Cyp33 is a 33 kDa, RNA binding cyclophilin family protein. It was first identified 
in 1996 from human T-cells 
25
. It contains an RNA recognition motif (RRM) and a 
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Cyclophilin domain. The Cyclophilins are cyclosporin A binding proteins 
88
. To date 
there are at least 16 cyclophilins identified in humans. All the cyclophilins have the 
prolyl isomerase activity. The proline in the peptide bond exist mostly in cis 
conformation, this is the restricted conformation. The peptidyl prolyl isomerase catalyzes 
the cis-trans prolyl isomerization of the prolyl bond and thus assisting in the proper 
folding of the protein 
89
. Due to its peptidyl prolyl isomerase activity Cyp33 is also called 
PPIE or Cyclophilin E. The RRM of Cyp33 binds to poly-A or poly-U containing RNA. 
Cyp33 is a component of spliceosome and is involved in pre-mRNA splicing 
24
. Besides 
binding RNA, the RRM of Cyp33 binds to proteins. Previous studies from our lab have 
shown that the RRM of human Cyp33 directly binds to the 3
rd
 PHD finger of human 
MLL, and the interaction is not mediated by RNA binding. Moreover, the interaction 
between the Cyp33 and MLL PHD3 disrupts the interaction between Cyp33 and RNA 
87
. 
Over expression of Cyp33 resulted in increased recruitment of transcriptional co-
repressors like HDAC1 and Bmi-1 to the repression domain of MLL resulting in 
repression of MLL target genes 
23,27
. More importantly this interaction is evolutionarily 
conserved and occurs in Drosophila. Dcyp33 binds to the third PHD finger of Trithorax, 
a Drosophila homologue of human MLL. Also, over expression of Dcyp33 in Drosophila 
SL1 cells resulted in down-regulation of the Trithorax target genes, highlighting the 
evolutionarily conserved role of Cyp33 in transcriptional regulation 
57
.   
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The N-terminal RRM domain of Cyp33 can bind to RNA and also mediates the 
interaction of MLL PHD3 and Cyp33. The Cyclophilin domain of Cyp33 
contains prolyl isomerase activity. The region between the RRM and the 
Cyclophilin domain partially conserved and is known as the spacer region. The 
function of this region is unknown. 
 
Figure 4: Illustration of Protein Domains of Cyp33. 
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Furthermore, the PPIase activity is required for Cyp33 mediated transcriptional 
repression of MLL target genes 
26,29
. Though Cyp33 was identified as a prolyl isomerase 
in 1996, until recently the targets of the Cyp33 PPIase activity were not known. Wang et 
al., recently demonstrated that the proline1629 present in the linker region between PHD3 
and the bromo-domain of MLL is a target of the Cyp33 PPIase activity. The cis-trans 
isomerization of proline 1629 resulted in drastic conformational change allowing MLL 
PHD3 to bind to RRM of Cyp33, showing the requirement of PPIase activity for the 
transcriptional repression of target genes 
29
.  
JARID1 Histone Demethylases and their Functions 
Until the first H3K4 demethylase LSD1 was identified in 2004, the main 
mechanism to  erase methyl marks was thought to be through passive dilution through 
successive cell division. LSD1 is a dual specificity demethylase that demethylates 
H3K4Me1 and H3K4Me2 and H3K9me1 and H3K9me2 
90,91
. In 2006 and 2007, a series 
of reports discovered the JARID1 (KDM5) family of mammalian demethylase that 
demethylates mono-, di-, and tri-methyl histone H3-K4. The JARID1 family also known 
as the KDM5 (Lysine demethylase5) family comprises of JARID1A, JARID1B, 
JARID1C and JARID1D. Like MLL, these proteins are also conserved throughout 
metazoan. The Drosophila homologue of JARID1 is called Lid (Little Imaginal Disc) 
92
. 
All JARID1 family members have JmjN, ARID domain (AT Rich DNA Interacting 
Domain), PHD, zinc finger domains and a catalytically active JmjC domain that has the 
demethylase activity.   
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JARID1 family members,  the histone demethylases remove trimethyl (Me3) mark 
from histone H3K4. The Jumonji-C (JmjC) domain contains the demethylase 
activity; the ARID domain is required for DNA binding. The PHD3 of JARID1A and 
JARID1B bind to H3K4Me3. Thus JARID1A and JARID1B are erasers with 
embedded readers for H3K4Me3 and are different from other two family members 
JARID1C and JARID1D that lack a PHD3. 
Figure 5: JARID1 family histone demethylases. 
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The JmjN domain, ARID domains and zinc finger domains are all required for the 
demethylase activity of JmjC domain. The ARID domain binds to AT rich DNA 
sequences and thus imparts some specificity in binding to DNA. Of all the family 
members, JARID1A and JARID1B have similar domain architecture and are partially 
redundant in function 
93
. Both JARID1A and JARID1B are “erasers” with embedded 
“readers”. There are three PHD fingers in JARID1A and B. JARID1C and JARID1D lack 
PHD3. The 3
rd
 PHD finger of JARID1A and JARID1B act as a ligand for H3K4Me3. 
The 2
nd
 PHD finger of JARID1C specifically binds H3K9Me3 
35
. JARID1A is 
ubiquitously expressed, whereas JARID1B is expressed at low levels ubiquitously, except 
for the testis where there is higher level of expression. JAR1D1C and JARID1D are 
encoded by genes on the X and the Y chromosomes respectively. JARID1B was 
identified as an oncogene that is frequently over expressed in breast cancer. There is 
mounting evidence showing that JARID1B is over expressed in other human cancers like 
prostate, bladder, renal, and lung cancers, AML and CML.  Though JARID1A and 
JARID1B are implicated as oncogenes, JARID1C and D are considered as potential 
tumor suppressors. There are inactivating mutations in JARID1C in kidney cancer and 
JARID1D is deleted in prostate cancers 
86
. 
PHD Fingers of Other Chromatin-Associated Proteins 
The PHD finger was first identified in the homeo domain containing protein HAT 
3.1 in Arabidopsis and hence named as Plant Homeo Domain 
94
. PHD fingers are about 
60- 65 amino acids in length typically. However some atypical PHD fingers are about 80 
amino acids long. More than 200 proteins in the nucleus contain PHD finger and a 
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majority of them are transcription regulators and chromatin associated proteins 
95
. They 
have conserved regularly spaced cysteines, similar to that of the zinc fingers present in 
many transcription factors. Cys4–His-Cys3 is the amino acid sequence in a PHD finger 
that is required to co-ordinate two zinc atoms. Some atypical PHD fingers like that of 
RAG2 have Cys3-His2-Cys3 architecture to co-ordinate the zinc atoms 
96
. Besides its 
role in DNA binding and mediator of protein–protein interactions, the biological function 
of PHD fingers have remained elusive since its discovery in 1993. The research over the 
past decade has highlighted the PHD fingers as readers or binding modules for modified 
and unmodified histones. In 2006, at least 6 different groups reported that the conserved  
aromatic residues present in PHD fingers of BPTF, NURF, ING2 and Yng1 forms an 
aromatic cage which serves as a binding pocket for trimethylated histone H3K4 
35,97,98
. 
Now there are about 15 different chromatin associated proteins that have PHD fingers 
that recognize H3K4Me3 (Table1) 
35
.  
In addition to binding to methylated H3K4, the PHD fingers are now known to 
bind unmethylated H3K4, H3K36me3, H3K9Me3, H3K14 ac and H3R2 
35
 . PHD fingers 
of BPTF, RAG2 and BHC30 recognize multiple but specific histone modifications. This 
combinatorial modification recognition by a PHD finger is plausible because the ligands 
(histones) may bind to different regions in the PHD finger and may influence one 
another’s binding positively 98.  Also, multiple modifications are recognized by the same 
protein; for example, the bromo-domain of BPTF binds acetylated lysines and the PHD 
finger binds to H3K4Me3. In many of the chromatin associated proteins there are more 
than one PHD finger.  The importance of the adjacent PHD fingers present in a same 
protein in recognizing the cognate histones is not yet well characterized. DPF3b PHD 
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fingers are the only known example wherein the PHD finger1 and 2 of DPF come 
together and form a binding pocket to recognize H3K14ac (Zeng et al. 2010) 
99
.  
The PHD fingers are present in writer proteins that post translationally modify 
histones, eraser proteins that remove the histone modifications or may be present in a 
chromatin associated protein that recruits other transcriptional effector proteins. Hence 
the functional outcome of the PHD finger recognizing its cognate histone depends on the 
protein the PHD finger is present. 
Mutations of PHD Fingers 
Point mutations in the PHD finger region (N216S, V218I, and G221V) of ING 
family tumor suppressors are found in human cancers. These mutations result in about 
10-40 fold decrease in the PHD finger binding to H3K4Me3 (Baker et al. 2009). Point 
mutations in the PHD finger region of RAG2 which affect the H3K4Me3 binding leads to 
decreased catalytic activity of the recombinase enzyme which is important for V(D)J 
rearrangement required for the development of B/T cells. An immunologic disorder, 
Omenn syndrome is a classic example where in the mutations in the PHD finger of 
RAG2 affect the H3K4Me3 binding are common. Especially there is higher incidence of 
W453R mutation in patients with Omenn’s syndrome. This mutation specifically occurs 
in one of the three amino acids that contribute to the aromatic cage formation that 
disrupts the RAG2 PHD and H3K4Me3 interaction 
100
. PHD fingers that bind H3K4Me3 
can become a part of another protein by chromosomal translocations. Thus the fusion 
protein will have the acquired ability to bind H3K4Me3. The NUP98-JARID1A fusion 
occurs in rare cases of AML. NUP98 is a nucleoporin that shuttles between the nuclear 
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pore complex and regions of active transcription. The PHD finger 3 of the JARID1A 
histone demethylase or PHF23 that binds to H3K4Me3 can fuse to NUP98 resulting in a 
fusion protein. Both JARID1A and PHF23 PHD fingers can bind to H3K4Me3 
explaining a common mechanism for leukemogenesis 
101
.   
Table 1: PHD fingers of Chromatin-Associated Proteins that Bind H3K4Me3 
 
  
Protein Host Complex
Function of the complex
(function of the protein)
Biological Outcome
BPTF NURF ATP-dependent chromatin remodeler
Nucleosome mobility
Transcription activation
ING1 mSin3a/HDAC1 Histone deacetylase Transcription repression
ING2 mSin3a/HDAC1 Histone deacetylase Transcription repression
ING3 NuA4/Tip60 Histone acetyltransferase Transcription activation
ING4 HBO1 Histone acetyltransferase Transcription activation
ING5
MOZ/MORF
HBO1
Histone acetyltransferase
Transcription activation
JARID1A (KDM5A) (Histone demethylase) Transcription repression
KDM7A (Histone demethylase) Transcription activation
KIAA1718 (Histone demethylase)
MLL1 COMPASS-like (Histone methyltransferase)
Histone methyltransferase
Transcription activation
PHF2 (Histone demethylase) Transcription activation
PHF8 (Histone demethylase) Transcription activation
PHO23 Rpd3 Histone deacetylase Transcription repression
PYGO1/2 PYGO1/2/BCL9 Transcription factor
Wnt signaling
Transcription activation
RAG2 RAG1/2 V(D)J Recombinase Recombination
TAF3 TFIID Transcription factor Transcription activation
YNG1 NuA3 Histone acetyltransferase Transcription activation
YNG2 NuA4 Histone acetyltransferase Transcription activation
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CHAPTER 3 
MATERIALS AND METHODS 
Cloning Techniques Used In This Study 
Restriction Enzyme Digestion and Inactivation: Restriction endonuclease digestion of 
plasmid DNA was performed using the Fast Digest enzymes from Fermentas. 1-2µg of 
plasmid DNA was digested with 1U of the enzyme and 1µl of 10X Fast Digest buffer in a 
10µl reaction for 10-15 minutes at 37°C. The enzyme was heat activated for 10 minutes; 
the temperature varies from 65-80°C, depending on the enzyme used. 
Dephosphorylation of the vector: If the ends of the restriction digested vector DNA 
were compatible, the vector can re-ligate and form colonies upon transformation. To 
avoid this, after restriction digestion the vector fragment was dephosphorylated using 1µl 
of Fast Alkaline Phosphatase from Fermentas at 37°C for 10 minutes. The enzyme was 
heat inactivated at 80°C for 10 minutes. 
Isolation of DNA restriction fragments from agarose gels: The digested DNA and an 
appropriate molecular weight marker were separated in 1% agarose gels in 1x TAE 
buffer (400mM Tris-acetate, 1mM EDTA). The gel was stained in ethidium bromide and 
destained in de-ionized water. The bands were visualized under UV and the DNA 
fragment of interest was identified based on the expected molecular weight. The DNA 
fragment of interest was excised from the gel. DNA was extracted from the gel slice 
using the Promega PCR clean up kit. 
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The extracted vector and insert DNA fragments were quantified by running on 1% 
agarose gel containing ethidium bromide and compared to the bands of known 
concentration and weight using a marker. 
Ligation: The ligation was performed using T4DNA ligase from Fermentas. The gel 
purified vector and insert DNA fragments were mixed in 3:1 molar ratios in a 10µl 
reaction containing 1U of T4 DNA ligase from Fermentas and  1µl of 10X Ligase buffer 
containing ATP. Thermoligations were performed in a PCR machine overnight. 
Transformation: 2µl of ligation reaction was electroporated into DH10B bacteria using 
a cell porator from GIBCO BRL according to the manufacturer’s protocol. 500µl of LB 
media was added to the electroporated bacteria and incubated at 37°C with shaking at 225 
rpm for 1 hour and then 100µl of the bacteria were plated on a LB ampicillin (100µg/ml) 
plate and incubated for 16-18 hours at 37°C.  
Identification of the bacterial clone containing the ligated vector and insert plasmid: 
Individual colonies were picked and grown in 5ml of LB broth containing 100µg of 
ampicilin (or appropriate selection antibiotic resistance conferred by the plasmid). For 
larger constructs 50µg of ampicilin was used. The cultures were grown over night at 
37°C in a shaking incubator at 225 rpm. The plasmid DNA was extracted from the 
bacteria using the Promega Plasmid Purification kit (mini preps). The plasmids 
containing the inserts in right orientation were identified by restriction digestion. To 
obtain larger quantity of DNA, Maxi prep was performed using Qiagen Maxi Prep 
Plasmid DNA purification kit. 
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Table 2. Expression Plasmids used in this study 
Plasmid Vector 
size 
(Kb) 
Insert 
size 
(Kb) 
Flanking 
Restriction sites 
Protein 
length/ 
Amino acids 
Source or 
Cloned by 
pCep4 10.2  ----- ------- -------- Invitrogen 
pCep4 FLAG Cyp33 10.2 3.0  KpnI…XhoI Full length Ute 
Osmers 
pCep4 FLAG PPiase 
mutant 
10.2 3.0 KpnI…XhoI Full length 
(R191A, 
F196A) 
Ute 
Osmers 
pCXN2 FLAG MLL-N 5.2 6.5 EcoRI…XhoI 1-2158 James 
Hsieh 
pcI FLAG MLL-N  5.7 6.5 XhoI 1 to 2665 James 
Hsieh 
pGEX4t1 GST MLL 
PHD2 
4.9 0.2 BamHI…XhoI 1480 to 1540 This study 
pGEX4t1 GST MLL 
PHD3 
4.9 0.32 EcoRI…XhoI 1531 to 1635 Ute 
Osmers 
pGEX4t1 GST MLL 
PHD3 M1585A 
4.9 0.32 EcoRI…XhoI 1531 to 1635 
M1585A 
This study 
pGEX4t1 GST MLL 
PHD3 M1606D 
4.9 0.32 EcoRI…XhoI 1531 to 1635 
M1606D 
This study 
pGEX4t1 GST MLL4 
PHD3 (ALL2) 
4.9 0.32 EcoRI…XhoI 1335 to 1396 This study 
MSCV neo 6.4 ----- -------- -------- Clontech 
MSCV neo MLL-N 
wild type 
6.4 8.0 XhoI 1 to 2665 Wei Wei 
Diaz lab 
MSCV neo MLL-N 
M1585A 
6.4 8.0 XhoI 1 to 2665 This study 
MSCV neo MLL-N 
M1606D 
6.4 8.0 XhoI 1 to 2665 This study 
MSCV puro 6.3 ----- ------- -------- Clontech 
MSCV puro FLAG 
MLL-ENL 
6.3 4.8 EcoRI…XhoI MLL 1-1394 
ENL 372-
560 
Wei Wei 
Diaz lab 
MSCV puro FLAG 
MLL-AF9 
6.3 4.35 EcoRI…BglII MLL 1-1362 
AF9 481-568 
Wei Wei 
Diaz Lab 
pCMV Myc 
MLL C  
3.8 3.75 XhoI  2720-3969 James 
Hsieh 
Shcontrol pSIREN-
RetroQ 
6.4  BamH1…EcoRI -------- Ralf 
Janknecht 
Sh JARID1b pSIREN-
RetroQ 
6.4  BamH1…EcoRI -------- Ralf 
Janknecht 
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Generation of MSCV neo MLL-N M1585A and M1606D 
Step 1: Generation of MLL PHD3 mutants in pGEMT EZ 
pCXN2 FLAG tagged MLL-N was kindly provided by Dr. James Hsieh from 
Memorial Sloan Kettering. A 2.3kb fragment of MLL-N which comprises the CXXC 
domain and PHD fingers was digested with AatII and NdeI and ligated into AatII and 
NdeI sites of pGEMT EZ (Promega). 20ng of this plasmid DNA was subjected to PCR 
based site directed mutagenesis using a forward primer containing the mutation and a 
reverse primer which anneals 200 bp downstream of the forward primer. The PCR 
products were digested with DpnI to get rid of the remaining input plasmid DNA and 
then transformed into DH10B bacteria. The transformants harboring the mutations were 
verified by DNA sequencing.  
Table 3. Primers Used for Site Directed Mutagenesis 
Primer Name Sequence 5`-3` 
MLL PHD3 
M1585A F  
GACTATGAGAGTAAGGCGATGCAATGTGGAAAG 
MLL PHD3 
M1606D F 
GAGAATCTTTCAGATGAGGACTATGAGATTCTATCTAATC 
MLL PHD3 R GGAAGGTATACTCTCCTCTGTCTC 
 
Step 2: Cloning of the full length MLL-N wild type and mutants in pBK(-) 
Wei Wei in our lab cloned the 8.0kb wild type MLL-N into XhoI site of pBK (-) 
(Stratagene) from pcI MLL-N provided by Dr. Hsieh. The PHD3 mutants in pGEMT EZ 
were digested with AatII and NdeI, these 2.3kb fragments were swapped in for the wild 
type AatII …NdeI fragment in pBK(-) full length MLL-N.  
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Step 3: Cloning of MLL-N wild type and the mutants into MSCV neo 
The 8.0kb MLL-N wild type or the mutants in pBK were digested with XhoI and 
ligated into the XhoI site of MSCV neo. The orientation of the insert was verified by 
restriction digestion and further confirmed by DNA sequencing. 
Cell culture 
The human cell line used in this study is HEK 293T. HEK 293T cells were grown 
in DMEM containing 10% FBS and 1% penicillin-streptomycin. The cells were 
maintained in culture by trypsinizing and splitting every 2 days. The mouse cell line used 
in this study is Mouse Embryonic Fibroblast (MEF). They are wt for MLL and grown in 
DMEM containing 10% FBS and 1% penicillin-streptomycin B-mercaptoethanol. Cells 
were trypsinized and re-plated every 2 days. 
Transfection 
HEK 293T cells were transfected using Lipofectamine-2000 (Invitrogen). Cells 
were trypsinized and plated in a 10cm dish at least 4 hours prior to transfection. The cells 
were approximately 40% confluent at the time of transfection. 15-20µg of plasmid DNA 
was transfected with 30µl of lipofectamine according to the manufacturer’s protocol. 
DNA-lipofectamine complex was allowed to form at room temperature for 20 minutes in 
serum free media. The transfection mixture was added to the cells. The media was 
changed after 12 hours and the cells were harvested after 48 hours after transfection for 
experiments. If the transfected plasmids encode for drug resistance, then transfectants 
were selected using the specific drug (puromycin 1µg/ml for HEK 293T cells).  
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Retroviral packaging and concentration 
3x10
6 
ecotropic Phoenix virus packaging cells (Garry Nolan / Orbigen) were 
plated in a 10cm dish; five plates were plated per sample. The following day, 25µg of 
retro viral plasmid DNA per 10cm dish was transfected using calcium phosphate; to 
enhance the viral production 2.5µg of viral packaging plasmid was co-transfected. 14-16 
hours post transfection 7ml of fresh DMEM containing 10% FBS and 1% Pen/Strep was 
added to each plate and the cells were incubated at 32°C with 5% CO2. The Phoenix eco 
cells are adherent cells; the retroviral plasmid transfected cells release the viruses into the 
media. Hence the media containing the viruses were collected from the transfected cells 
and stored at 4°C. Fresh media was added to the cells, the cells were incubated at 32°C 
with 5% CO2 to make more viruses. After 24 hours the media was collected again and 
combined with the media already collected, then spun down to remove any cell debris. 
The solution containing the retroviruses were concentrated about 7 times using Centricon 
Plus 70 filters (Millipore) by centrifugation in a swing bucket JS 7.5 rotor.  Concentrated 
retroviruses were aliquoted, snap frozen, and stored at -80°C. The plasmids used for 
retroviruses were MSCV neo, MSCV neo MLL-N wt, MSCV neo M1585A, MSCV neo 
M1606D, and MSCV puro MLL-AF9 (Table 2). 
Titration of Retrovirus 
8.5x10
4
 Rat 1a cells were plated in 6 well plates in DMEM containing 10% FBS 
and 1% Pen/Strep. The following day, Rat1a cells were infected with serial dilutions of 
the virus from 1x10
3
 to 1x10
6 
with 16µg/ml of polybrene in 1ml of  DMEM containing 
10% FBS. After 2 hours, the media containing polybrene was removed from the plates 
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and replaced with DMEM and 10% FBS. 24hours post-infection, the media was removed 
and fresh media containing 1mg/ml of G418 was added to select for the cells that have 
been transduced with the viruses. After the no virus control cells died (about 10 days), the 
colonies formed  by virus infected cells were washed with PBS and stained with 1ml of a 
solution of  0.1gm methylene blue in 60 ml Methanol for 5 minutes.  Plates were rinsed, 
dried, and then colonies were counted to determine the virus titer.
 
     Retroviral Transduction of MEFs 
 About 0.5x10
6 
were plated on 6 well plates. After 3-4 hours the old media was 
removed and replaced with 1ml of  media (DMEM 10% FBS, 1% Pen Strep) containing 
750µl of concentrated retro virus, 4µg/ml of polybrene, 1 M HEPES was added.  The 
plates were incubated at 32°C with 5% CO2 for 4 hours. Then the media containing the 
virus was removed and replaced with fresh MEF media. Since the plasmid packaged into 
the virus encodes for neomycin resistance, the transductants were selected using G418 
1mg/ml.  
Isolation of Cells from Mouse Bone Marrow 
One C57Bl/6 mouse, age 8-12 weeks, was sacrificed by CO2 inhalation. Tibias 
and femurs were collected in a cell culture dish with RPMI 2% FCS. Excess tissue was 
removed from bones with sterile gauze.  8ml RPMI 2% FCS was added to a 10cm plate. 
Using a 25 gauge 1.5” needle and media in the dish, bone marrow was flushed into the 
plate until bones appear white. Cells were separated from the rest of the tissue debri by 
passing through a mesh. Cells were spun down at 1500 rpm for 5 minutes at 4°C, then 
resuspended in 5ml 1X cold sterile red cell lysis buffer (10X RBC lysis buffer: 83gm 
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NH4Cl, 10gm NaHCO3, 0.37gm EDTA in 1l H20) and incubated on ice for 5 minutes. 
Cells were spun down at 1500 rpm for 5 minutes at 4°C, then resuspended in 10 ml PBS 
2% FCS to create a single cell suspension and then proceeded with C-Kit positive 
selection to enrich for the hematopoietic progenitors population. 
C-Kit Positive Selection of Mouse Bone Marrow Cells 
To select for the C-Kit+ hematopoietic progenitor cells in the mouse bone 
marrow, I followed the Easy Sep Mouse CD117 (c-Kit) Positive Selection Kit (#18757 
Stem Cell).  Cells were resuspended at 100x10
6
 cells per ml in PBS 2% FBS, in a Falcon 
5ml Polystyrene Round-Bottom Tube.  CD117 antibody (with Fc blocker) was added to 
cells at 70μl/ml cells.  Solution was mixed and incubated at room temperature for 15 
minutes.  Easy Sep PE selection cocktail was added at 70μl/ml cells.  Solution was mixed 
and incubated at room temperature for 15 minutes. Magnetic nanoparticles were mixed 
by pipetting 5 times, and then added to the cell solution at 50μl/ml cells.  Solution was 
mixed and incubated at room temperature for 10 minutes.  Cell suspension was next 
brought up to 2.5mL with PBS 2% FBS. Cells were mixed by pipetting 2-3 times.  Tube 
without cap was placed in chilled Easy Sep magnet and allowed to sit for 5 minutes.  
Without removing the tube from the magnet, the supernatant was carefully removed.  The 
tube was removed from magnet and 2.5 mL PBS 2% FBS was added to cells, pipetting 2-
3 times to mix.  Magnet separation was repeated for a total of four 5 minutes separations.  
Cells were resuspended in 1.5mL PBS 2% FBS and counted. Cells were plated overnight 
in a round bottom 96 well dish at 1 million per 1mL of  RPMI 1640 media with 10% FBS 
(heat inactivated at 55°C for 1hour) , 1% Pen-Strep, and supplemented  with100ng/ml 
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SCF, 10ng/ml IL3, 10ng/ml IL6, 10ng/GM-CSF.  Sterile H20 was added to wells 
surrounding the cells to keep them from drying out. 
Retroviral Transduction of C-Kit+ Hematopoietic Progenitors
 
The day after C-Kit positive selection, 200,000 cells C-Kit positive hematopoietic 
progenitors, 1.5ml of concentrated retro virus, 15.0μl 1M HEPES, 8μg of polybrene 
(Sigma) were mixed and the volume was made up to 2ml with RPMI 1640 media 
containing 10% FBS. Further, spinoculated at 3000 rpm in Beckman GS6KR centrifuge 
at 32°C for 4 hours. After spinoculation, without disturbing the cell pellet, the 
supernatant containing the polybrene and virus was carefully removed. The cells were 
then resuspended in RPMI 1640 media with 10% FBS (heat inactivated at 55°C for 
1hour) , 1% Pen-Strep, and supplemented 100ng/ml SCF, 10ng/ml IL3, 10ng/ml IL6, 
10ng/GM-CSF;  and plated in 96 well plate. To ensure an efficient transduction of 
hematopoietic progenitors, a second spinoculation was performed the following day and 
cells were resuspeded in RPMI 1640 media with 10% FBS (heat inactivated at 55°C for 
1hour) , 1% Pen-Strep, and supplemented 100ng/ml SCF, 10ng/ml IL3, 10ng/ml IL6, 
10ng/GM-CSF and plated in 96 well plate. 
Liquid Culture of Transduced Hematopoietic Progenitors 
The day after retroviral transduction of hematopoietic progenitors, a portion of the 
cells ( about 70,000 rest 30,000 was used for colony assay) were selected with G418 
1mg/ml (MSCV neo) or puromycin (MSCV puro) 1μg/ml depending on the resistance 
marker encoded by the plasmid DNA used for retro virus production and cultured in 
RPMI 1640 media containing 10% FBS (heat inactivated at 55°C for 1hour), 1% Pen-
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Strep, 100ng/ml SCF, 10ng/ml IL3, 10ng/ml IL6, 10ng/ml GM-CSF. Every 2 -3 days 
depending on their growth rate the media was removed and replaced with fresh media 
containing the indicated cytokines and selection drugs. After 4 days of selection cells 
transduced with MSCV neo, MLL-N wt, M1585A, or M1606D were harvested for RNA 
extraction.  
Hematopoietic Progenitors Colony Formation Assay 
The day after retroviral transduction of hematopoietic progenitors, 30,000 cells 
were added to 3ml of methyl cellulose supplemented with 100ng/ml SCF, 10ng/ml IL3, 
10ng/ml IL6 ( Stem cell technologies). Additionally, 10ng/ml GM-CSF and the selection 
drug G418 (1mg/ml) or puromycin (1μg/ml) was added and mixed very well by 
vortexing. About 1ml of the mixture was plated on to 35mm petri-dish. The platings were 
performed in duplicates. About 10,000 cells were plated in each plate for MSCV neo, 
MLL-N wt, M1585A or M1606D; about 1,000 cells were plated in each plate for MLL-
AF9 transduced cells. The plates were placed in humid chamber and incubated at 37°C 
with 5% CO2 and left undisturbed for a week. The hematopoietic progenitors should 
proliferate and form colonies on methyl cellulose. After a week, the number of colonies 
in each dish was counted. The transformation of hematopoietic progenitor was assessed 
by dissociating the colonies and re-plating the cells in methyl cellulose successively. 
RNA Extraction, DNAseI treatment, cDNA synthesis and qRT-PCR 
            5x10
6
 to10x10
6
 cells were pelleted by centrifugation. The loosened cell pellets 
were lysed in 1ml of TRIzol
TM 
(Invitrogen). 200µl of chloroform was added to the 
samples and mixed very well. The samples were incubated at room temperature for 2-3 
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minutes and then centrifuged at 12000 rpm for 12 minutes at 4°C. The upper layer (the 
aqueous phase) was carefully transferred to a fresh tube and the RNA was precipitated by 
adding an equal volume of isopropyl alcohol followed by centrifugation at 12000 rpm for 
10 minutes. The pellet was washed once with 75% ethanol prepared in diethyl 
pyrocarbonate (DEPC) treated water. RNA pellet was air dried for 5-7 minutes and 
dissolved in 50µl of DEPC treated water by incubating at 55°C for 5 minutes. 
Concentration of the RNA at 260nm was measured using Nanodrop 2000c. 
 The RNA extracted by the above mentioned method may have some amount of 
DNA which will confound the RT-PCR results. Hence, the RNA preparation has to be 
subjected to DNAseI digestion. About 3µg of RNA was digested with DNAseI 
(Fermentas) according to the manufacturer’s protocol. The DNAseI was inactivated by 
adding 50mM EDTA at 65°C for 10 minutes. Each DNAseI treated RNA sample was 
split into two halves. One half was used for cDNA synthesis with reverse transcriptase; 
the other was used as a control for DNAseI treatment wherein cDNA synthesis was 
performed without adding the reverse transcriptase (no RT control). cDNA will not be 
made in no RT control , hence any amplification detected in this sample will be from the 
remaining DNA present in the RNA sample. cDNA synthesis was performed  using the 
high capacity cDNA synthesis kit from Applied Biosystems according to the 
manufacturer’s protocol. cDNA samples were diluted 1:5 in nuclease free water and 
qRT-PCR was performed with GoTaq Sybr green  from Promega. PCR for a specific 
primer set was performed in triplicates for each cDNA sample in a 96 well plate in ABI 
3700 real time PCR machine. Sybr green is a fluorescent dye that intercalates DNA, and 
fluorescent signal at every cycle is recorded. Cycle threshold (Ct) value is the measure of 
 44 
 
 
 
the amplicon signals that are detected at the linear phase of amplification and are above 
the background. Ct value is obtained by analyzing the raw data using the ABI PRISM 
7300 software. The ct values (cycle threshold value) were obtained by performing the 
analysis using ABI Prism 7300 software.  
Table 4. Human qRT-PCR Primers 
Primer Name Sequence 5'-3' 
ACTB F CGTACCACTGGCATCGTGAT 
ACTB R GTGTTGGCGTACAGGTCTTTG 
GAPDH F 261 ATGGCAAATTCCATGGCACCGT 
GAPDH R 417 ATGGTGGTGAAGACGCCAGT 
B2M F TGCTGTCTCCATGTTTGATGTATCT 
B2M R TCTCTGCTCCCCACCTCTAAGT 
HPRT1 F TGACACTGGCAAAACAATGCA 
HPRT1 R GGTCCTTTTCACCAGCAAGCT 
PGK1 F CTGTGGGGGTATTTGAATGG 
PGK1 R CTTCCAGGAGCTCCAAACTG 
TBP F TATAATCCCAAGCGGTTTGC 
TBP R GCTGGAAAACCCAACTTCTG 
HOXA9 F TCCCACGCTTGACACTCACACTTT 
HOXA9 R AGTTGGCTGCTGGGTTATTGGGAT 
HOXC8 F TGGAAACCTGAAGGAGATGTGGGT 
HOXC8 R AAACAGGGAAGGAGAGGAAGGCAT 
CDKN1B F CCGGCTAACTCTGAGGACAC 
CDKN1B R CTTCTGAGGCCAGGCTTCTT 
MEIS1 F CAGAAAAAGCAGTTGGCACA 
MEIS1 R TCATGCCCATTCCACTCATA 
MYC F CCTACCCTCTCAACGACAGC 
MYC R CTCTGACCTTTTGCCAGGAG 
CYP33 F TCCAGGCCAGTTTGGTCAGATGAT 
CYP33 R CCGGCTTGTTCCCAATCTTGATGT 
MLL F ATGTGGAAAGTGTGATCGCTGGGT 
MLL R TGCCGCTCAGTACAGTTCACACAA 
KDM5A F TGTCCTAAATGTGTCGCCGAGGAA 
KDM5A R TGTGGGAACCATATGGACTGGCAT 
KDM5B F AATTTGGCAGTGGCTTTCCTGTCC 
KDM5B R CTGCTCCATCACTGGCATGTTGTT 
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Table 5. Mouse qRT-PCR Primers 
Primer Name Sequence 5'-3' 
m Actb F GGCTGTATTCCCCTCCATCG 
m Actb R CCAGTTGGTAACAATGCCATGT 
m Gapdh F GTGAACGAGAAGGACTATAACCC 
m Gapdh R GGCTGTGTAGGAATGGACTG 
m Hoxa9 F TACTATGTGGACTCCTTCCTGC 
m Hoxa9 R TTCCACGACGCACCAAACAC 
m Hoxc8 F GACGCCTCCAAATTCTATGGC 
m Hoxc8 R AGACGAGTTCTGATTTAAGTGGCC 
m Cdkn1b F CGCCAGACGTAAACAGCTCCGAATTA 
m Cdkn1b R AGAGGCAGATGGTTTAAGAGTGCC 
m Cdkn1a F TGTCTGAGCGGCCTGAAGATT 
m Cdkn1a R AGACCAATCTGCGCTTGGAGTGAT 
m Meis 1 F CTCCTCTGCACTCGCATCAG 
m Meis 1 R CCATGGCGTTGGTATGAGCT 
m Myc F CCCACCACCAGCAGCGACTC 
m Myc R GCGGAGGTTTGTGGCCT 
m Pu.1 F TGGAACAGATGCACGTCCTCGATA 
m Pu.1 R TCCAAGCCATCAGCTTCTCCATCA 
 
Fold change in gene expression was calculated by normalizing the average ct value of 
gene of interest for a given sample to the ct value for a house keeping gene for the same 
sample. Relative fold change in gene expression was calculated by setting the control to 
one and comparing the change in expression of other samples with respect to the control. 
Chromatin immunoprecipitation (ChIP) followed by quantitative PCR 
  10x10
6
 cells in 10ml of media were cross linked with formaldehyde (1% final 
concentration) for 15 minutes at room temperature.  The cross linking was stopped by 
adding 1ml of 1.25 M glycine. The cells were washed with cold PBS twice and pelleted 
at 2000 rpm. To the cell pellet 500µl cell-lysis buffer (3mM MgCl2, 10mM NaCl, 10mM 
Tris (pH 7.4) and 0.1% NP40) containing protease inhibitor (cocktail from Roche) was 
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added and incubated on ice for 15 minutes with intermitten vortexing every 5 minutes.  
The samples were centrifuged for 5 minutes at 2000 rpm at 4°C. The supernatant was 
removed and to the pellet 500µl of nuclear lysis buffer (1% SDS, 10mM EDTA, 50mM 
Tris (pH 8.0)) containing protease inhibitor was added and sonicated on ice to shear the 
DNA to an average length between 200 bp to 1000 bp. The sonication was performed 
using a Cole Parmer, High Intensity Ultrasonic Processor/Sonicator, 50 watt model with a 
2mm tip set to a power of 4 or 5. 293T cells were sonicated at setting 4, 6 pulses, 5 times. 
MEFs were sonicated at setting 5. The samples were centrifuged for 10 minutes at 13,000 
rpm at 4°C. The debri was removed. The supernatant (nuclear lysate) was used for the 
immunoprecipitations. 50µl of the nuclear lysate was diluted 10 times with ChIP dilution 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.0), 
167 mM NaCl) containing protease inhibitor, to which indicated amount of primary 
antibody (Table 6) and 20µl of Protein-A magnetic beads (Millipore) were added and 
mixed very well and immunoprecipitations were performed on an overhead turner 
overnight at 4°C. 10µl of nuclear lysate from each sample was kept aside as input to 
normalize for the amount of DNA present in each sample. The magnetic beads were 
allowed to attach to the walls of the tube using a magnetic rack (Millipore) for 30 
seconds. The supernatant was discarded. The magnetic beads protein A/ antibody/ 
chromatin complexes were washed in 500µl the following buffers for 3-5 minutes with 
rotation at 4°C.  Low Salt Wash Buffer: (0.1% SDS, 1% Triton X-100, 2mM EDTA, 
20mM Tris-HCl (pH 8.0), 150mM NaCl), High salt wash buffer: (0.1% SDS, 1% Triton 
X-100, 2mM EDTA, 20mM Tris-HCl (pH 8.0), 500mM NaCl), LiCl Wash buffer: 
(0.25M LiCl, 1% IGEPAL-CA630 or NP40, 1% Deoxycholic acid (sodium salt), 1mM 
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EDTA, 10 mM Tris (pH 8.0)) and TE Buffer: (10mM Tris-HCl (pH 8.0), 1mM EDTA). 
Bound DNA was eluted from the magnetic beads using 100µl elution buffer (0.1M 
NaHCO3, 1% SDS) and1µl of Proteinase-K 10mg/ml, mixed very well and incubated at 
62°C for 2 hours with rotation. The Proteinase-K was inactivated at 95°C for 10 minutes. 
The protein-free DNA was eluted from the magnetic beads. The DNA was recovered and 
purified using Mol Bio PCR clean up kit according to the manufacturer’s protocol. 
Similar to the IP samples the inputs were also processed for elution and Proteinase-K 
digestion and purification of DNA. The eluted DNA was diluted 5 times in nuclease free 
water and qPCR was performed in  triplicates for each sample in a 96 well plate in ABI 
3700 real time PCR machine with the primers specific for the gene of interest (Table 7 
and Table 8) using the GoTaq Sybr green  from Promega. The fold recruitment of a 
specific chromatin associated protein was calculated by normalizing the amount of 
chromatin immunoprecipitated DNA to the amount of input DNA, and subtracting from 
the background (IgG pull down) levels. The fold enrichment for the histone modifications 
was calculated by normalizing first to the input levels and then to the amount of histone 
H3 levels present at the region of interest. 
Table 6. Antibodies Used in ChIP 
Antibody Manufacturer/Catalogue 
#  
Amount used/ ChIP 
Anti histone H3 Millipore 05-499 
Abcam ab1791 
5µl 
Anti histone H3K4Me3 Millipore 17-614 3µl 
Anti acetyl histone H3  Millipore 06-599 5µl 
Anti acetyl histone H3K27 Millipore 07-360 5µl 
Anti JARID1A Abcam ab70892 7.5µl 
Anti JARID1B Abcam ab50958 7.5µl 
Rabbit IgG (negative control) Millipore 12-370 5.0µl 
Mouse IgG (negative control) Millipore 12-371B  5.0µl 
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Table 7. Human ChIP Primers 
Primer Name Sequence 5'-3' 
ACTB Promoter F TGCACTGTGCGGCGAAGC 
ACTB Promoter R TCGAGCCATAAAAGGCAA 
GAPDH Promoter F TACTAGCGGTTTTACGGGCGCACGT 
GAPDH Promoter R TCGAACAGGAGGAGCAGAGAGCGA 
B2M Promoter F AGACTTCCCAAATTTTGCCATCCTA 
B2M Promoter R AAAGGCCTGAAATGTTAGTGTTGAGT 
BGLOBIN Promoter F AGGGAGGGCTGAGGGTTTGA 
BGLOBIN Promoter R CAGGGTGAGGTCTAAGTGATGACA 
Histone H4 Promoter F AAATGGTGGGATCACAGACG 
Histone H4 Promoter R CGAGCTTCTTGTTTCCGTGT 
RPL10 Promoter F ACCCGTCTTCGACAGGACT 
RPL10 Promoter R GGAACGGAAGACGAGGAGAACAG 
HOXA9 Promoter F GCCAACCAAACACAACAGTC 
HOXA9 Promoter R CAAATCGCATTGTCGCTCTA 
HOXC8 Promoter F GGCGAGAGGCACCTTCACATCTAAATTC 
HOXC8 Promoter R AGAGAGAGAGAGAGAGAGAGAGAGAGATGGC 
CDKN1B (p27) F CCGGCTAACTCTGAGGACAC 
CDKN1B (p27) R ATACGCCGAAAAGCAAGCTA 
JARID1B Promoter F ACTTCTTCAGGGCAGGAACTCTGA 
JARID1B Promoter R TCCGCTGTCGATGGAGTTTATCCT 
HDAC1 Promoter F CGGCTATAGGTGAGCCCAGGA 
HDAC1 Promoter R AACAGACTTTCCTCCGGGT 
 
Table 8. Mouse ChIP Primers 
Primer Name Sequence 5'-3' 
m Actb Promoter F AGCAATAGCCGGAAAGCCAGATCC 
m Actb Promoter R ACCACTGGGGCTCGCCCTATG 
m Gapdh Promoter F AGAGAGGGAGGAGGGGAAATG 
m Gapdh Promoter R AACAGGGAGGAGCAGAGAGCAC 
m Hoxa9 Ch pro can F CACTGCCTGAGACCACAGAA 
m Hoxa9 Ch pro can R AGGGAGCCTGGAGTACTGGT 
m Hoxc8Promoter F AACCTGAGTTGACCTGATGGCTCA 
m Hoxc8 Promoter R CTAACTAATGGACAAGGCCAGCTT 
m Cdkn1b Promoter F CGGCCGTTTGGCTAGTTTGTTTGT 
m Cdkn1b Promoter R GGAGGCTGACGAAGAAGAAGATGA 
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Western Blot and Immunoprecipitation 
Cells were washed in PBS and pelleted down by centrifugation. Further, cell lysis 
was performed using IPH lysis buffer (50mM Tris-HCl (pH 8.0), 150mM NaCl, and 
5mM EDTA, 0.5% NP-40, 1X protease inhibitor (Roche) for 30 minutes on ice. The 
cellular debri were removed by centrifugation at 12000 rpm 10 minutes at 4°C. Protein 
concentration was estimated using BCA (Pierce) method. Depending on the abundance of 
the protein in the cell, anywhere from 500 to 1500µg of protein was made up to 1ml with 
1X IPH lysis buffer. To reduce non-specific binding, the lysate was pre-cleared with 
ProteinA/G beads (Roche), depending on the isotype of primary antibody used for 1hour 
at 4°C.  The pre-cleared lysate was used for immunoprecipitation with the primary 
antibody (at the concentration recommended by the manufacturer) along with ProteinA/G 
beads (Roche) over night at 4°C. The immunoprecipitated protein complexes were 
washed with lysis buffer for 4-5 times with 5 minutes intervals between each wash. After 
the final wash, 2X loading dye  (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 
0.004% bromophenol blue, 0.125 M Tris-HCl) was added to the beads and denatured at 
100°C and loaded onto SDS-PAGE (percentage of PAGE was ascertained based on the 
molecular weight of the protein to be immune blotted) and the protein was 
electrophorectically separated using the 1X Tris-Glycine running buffer (25 mM Tris 
base, 190 mM glycine, 0.1% SDS pH 8.0). The separated proteins were 
electrophoretically transferred to a PVDF membrane with a pore size of 0.45µM ( Pierce) 
using 1X pre-chilled transfer buffer (25 mM Tris base,190 mM glycine, 20% methanol) 
100 volts for 1 hour. After the protein was transferred to the membrane, to minimize the 
non-specific binding of the antibody, the membrane was blocked in 5% non-fat skim milk 
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in 1X TBS (24.23 g Tris-HCl, 80.06 g NaCl made up to 1L with water, pH to 7.6) for 1 
hour at room temperature. Then, primary antibody was diluted as per the dilutions in the 
table in 2.5% milk and added to the blot and left in the shaker over night at 4°C.  The 
following day the blot was washed in TBST (0.5ml of Tween 20 added to 1L of TBS), 10 
minutes, three times. Depending on the organism in which the primary antibody was 
raised, the corresponding secondary antibody (anti Rabbit or anti Mouse from Santa 
Cruz) was added for 1hour at room temperature. To get rid of the unbound antibody, and 
other non-specific binding the blot was washed three times with TBST and the blot was 
developed with Enhanced Chemiluminescence kit (ECL Super signal, Dura) from 
Pierce). 
 
Table 9. Primary Antibodies Used in Western Blot 
Antibody Manufacturer/Catalogue 
# 
Epitopes 
recognized 
Dilution 
Anti H3K4Me3 Abcam 12209 1-100  1:1000 
Anti MLL-N Dr.Thirman 1-371 1:1000 
Anti MLL-N Bethyl lab 1320-1380 1:2500 
Anti MLL-C Dr.James Hsieh 2829-2883 1: 10000 
Anti PPIE Novus Biologicals 
H00010450-A01  
2-101 1:1000 
Anti JARID1A Abcam ab70892 1675-1722 1:1000 
Anti JARID1B Abcam ab50958 125-325 1:1000 
Anti-FLAG M2 SIGMA F3165 DYKDDDDK 1:1000 
Anti HA Abcam 9110 YPAYDVPDYA 1:1000 
Western Blot for MLL-N 
8x10
6
 cells (MEF or 293T) were washed in PBS and centrifuged at 2000 rpm for 
5 minutes. The pelleted cells were then lysed in 300µl of cell lysis (3mM MgCl2, 10mM 
NaCl, 10mM Tris (pH 7.4) and 0.1% NP40) buffer for 15 minutes on ice with intermitted 
vortexing followed by centrifugation at 3000 rpm for 5 minutes at 4°C. To the pellet, 
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350µl of nuclear lysis buffer (1% SDS, 10mM EDTA, 50mM Tris (pH 8.0)) was added 
and chilled in ice for few minutes and then sonicated on ice at setting 5 for 3 pulses two 
times. The nuclear debri was removed by spinning at 12000 rpm for 10 minutes at 4°C. 
The protein present in the nuclear extract was quantified by BCA (Pierce) method; 100µg 
of the nuclear extract was mixed with 6X loading dye, denatured at 100°C for 5 minutes 
and loaded on 3-8 % tris acetate gel from Invitrogen. The proteins were 
electrophorectically separated using the 1X tris- acetate running buffer (Invitrogen) at 
160 volts for 1hour and 30 minutes. The separated proteins were electrophoretically 
transferred to a nitrocellulose membrane (High bond-C) with pore size 0.45µM 
(Amersham) using 1X pre-chilled transfer buffer containing 10% methanol (Invitrogen) 
at 100 volts for 3 hours. High molecular weight protein ladder from Fermantas was used 
a guide for assessing the separation of proteins on the gel and for the efficient transfer of 
protein to the nitrocellulose membrane. Following the transfer, blocking, primary 
antibody, secondary antibody staining and developing the membrane with ECL was done 
similar to the immune blotting for other proteins.  
Nucleosome pull down assay 
HEK 293T cells were transfected with 20µg of MSCV neo vector control; FLAG 
tagged MLL-N wt, M1585A or M1696D with Lipofectamine-2000 (Invitrogen) 
according to the manufacturer’s instruction.  After 48 hours about 1 to 2x107 cells were 
washed with PBS and resuspended in a ml of buffer A (10mM HEPES pH 7.9, 10mM 
KCl, 1.5mM MgCl2, 0.34M Sucrose, 10% glycerol, 1mM DTT) containing protease 
inhibitor cocktail (Roche). Triton X-100 was added to the final concentration of 0.1% and 
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the resuspended cells were homogenized in a dounce homogenizer (about 8-10 strokes) 
and then centrifuged at 4°C, for 5 minutes at 1300g. The nuclei in the pellet were washed 
in 1ml of buffer A and then lysed in buffer B (3mM EDTA, 0.2mM EGTA,1mM DTT) 
containing PI and the soluble and insoluble chromatin fraction was separated by 
centrifugation at 4°C for 5 minutes at 1700g. The insoluble chromatin was resuspended 
in 0.2ml of buffer M (10mM Tris pH 7.6, 10mM KCl, 1.5 mM CaCl2) prewarmed at 
25°C. 1U of micrococcal nuclease (New England Biolabs) was added and the digestion 
was performed for 5 minutes and 30 seconds. The reaction was stopped by adding 1mM 
EGTA and then centrifuged at 4°C 1700g for 5 minutes. An aliquot of the supernatant 
was de-proteinized using 1µl of 10mg/ml ProteinaseK at 62°C for 2 hours, followed by 
heat inactivation of Proteinase K at 90°C for 10 minutes. DNA was purified by PCR 
clean up kit and checked for predominant release of mononucleosomes in ethidium 
bromide containing 1% agarose gel. The length of the DNA wound around a nucleosome 
is approximately 146 bp.  The remainder of the supernatant was adjusted to 0.5ml with 
buffer C (15mM tris pH 7.6, 150mM NaCl, 1mM EDTA, 1mM DTT) containing PI and 
incubated over night at 4°C with FLAG beads. The immunoprecipitaites were washed 
with buffer C 4 times and eluted by boiling the beads in 2X SDS sample buffer for 5 
minutes. Aliquots of input and immunoprecipitated eluates were subjected to immunoblot 
analysis in a 15% SDS–PAGE and immunoblotted for H3K4Me3 (Abcam ab12209) 
according to the manufacturer’s instructions 102. 
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CHAPTER 4 
RESULTS 
Aim1: Determine the effect of Cyp33 over expression on transcription of MLL 
target genes.  
 
Previous studies from our laboratory have shown that the MLL PHD3 interacts 
with Cyp33 and over expression of Cyp33 results in transcriptional repression of MLL 
target genes. These previous studies used semi-quantitative RT-PCR to measure the 
effect of Cyp33 over expression on the transcription of MLL target genes 
23,57
. We have 
confirmed those results using qRT-PCR, a more quantitative approach to measure gene 
expression. The effect of Cyp33 over-expression on a panel of house-keeping genes was 
tested by qRT-PCR (Figure 6A). Since the ct values of β2- microglobulin (B2M) mRNA 
levels remain unchanged between vector-transfected control and Cyp33 over-expressing 
cells, B2M is used as a reference gene. The effect of Cyp33 on the expression of MLL 
target genes was measured by qRT-PCR (Figure 6B). Cyp33 over expression in 293T 
cells resulted in a 2 fold decrease in expression of  HOXA9, and 3.3 fold decrease in 
expression of HOXC8 and CDKN1B (p27) all of which are known MLL target genes 
11
 
Over-expression of Cyp33 was verified using qRT-PCR for CYP33 (Figure 6C ). 
Nucleosome density and certain histone modifications are correlates of 
transcription. To understand the mechanism of Cyp33 mediated transcriptional repression 
of MLL target genes, ChIP for H3 and histone marks at the promoters of MLL target  
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A. qRT-PCR for House-Keeping genes 
 
 
C. qRT-PCR for CYP33 
 
B. qRT-PCR for MLL target genes   
 
p = 0.0268 p = 0.0141 p = 0.0255 
293T cells were transiently transfected with pCep4 (vector) or pCep4-Cyp33 plasmids 
and harvested after 48 hours for RNA extraction, followed by qRT-PCR: A, for house-
keeping genes; B, for MLL target genes; C, for Cyp33. n=3, average of three 
independent experiments, error bars represent S.D. p values are from one- sample t- test. 
 
Figure 6: Effect of Cyp33 over expression on transcription of MLL target genes 
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ChIP for H3 at MLL target gene promoter 
 
 
 
 
 
 
 
 
p = 0.0061 p = 0.0146 p = 0.0439 
293T cells were transiently transfected with pCep4 (vector) or pCep4-Cyp33 
plasmids and harvested after 48 hours for ChIP for histone H3; Rabbit or mouse 
IgG was used as a negative control for the pull-down. n=3, average of 3 
independent experiments and error bar represents S.D. p values are from one 
sample t- test. 
 Figure 7: Effect of Cyp33 over expression on histone H3 density at MLL 
target gene promoters 
 56 
 
 
 
 
Figure 8: Effect of Cyp33 over expression on histone modifications at MLL target 
gene promoters 
A. ChIP for H3Ac at MLL target gene promoters 
 
 
 
 
 
 
 
 
 
 
 
 
  
293T cells were transiently transfected with pCep4 (vector) or pCep4-Cyp33 
plasmids and harvested after 48 hours for ChIP for: A, H3Ac; B, H3K4Me3, at MLL 
target genes. The fold enrichment of histone H3 modifications was calculated by 
normalizing the amount of histone H3 modification to the amount of total histone H3 
present at a given promoter. Rabbit or mouse IgG was used as a negative control for 
the pull-down. n=3, average of 3 independent experiments and error bar represents 
S.D. p values are from one sample t- test.  
B. ChIP for H3K4Me3 at MLL target gene promoters 
 
p = 0.0177 p = 0.0033 p = 0.0008 
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genes was performed. Over-expression of Cyp33 resulted in a statistically significant 
increase in histone H3 density at MLL target gene promoters which is consistent with the 
reduction in MLL target gene expression (Figure 7).  
Studies from our laboratory have shown that Cyp33 over expression did not affect 
the histone marks like H3K27Me3 and H3K9Me3 associated with gene silencing.  To test 
whether marks that are associated with active transcription change with Cyp33 over 
expression, a ChIP for transcription activation-associated histone marks like H3K4Me3 
and H3Ac at the promoters of MLL target genes was performed. To determine the fold 
enrichment of a particular histone modification at a given promoter, the amount of a 
particular H3 modification is normalized to the amount of total histone H3 present at the 
given promoter. ChIP performed with a pan-acetyl H3 antibody showed that over 
expression of Cyp33 resulted in a decrease in H3Ac levels at the promoters of MLL 
target genes HOXA9 (2 fold), HOXC8 (2 fold) and CDKN1B (5 fold) (Figure 8A). ChIP 
for H3K4Me3 (Figure 8B) showed that upon Cyp33 over expression there is a marked 
decrease of H3K4Me3 at the promoters of MLL target genes HOXA9 (3.7 fold), HOXC8 
(6.5), and CDKN1B (11.3 fold).  
The Cyp33 mediated decrease in H3K4Me3 marks at MLL target gene promoters 
may be due to active demethylation of H3K4Me3 marks. JARID1 family proteins are 
histone demethylases that demethylate H3K4Me3 and H3K4Me2 
33,34
. To determine if 
Cyp33 mediated decrease in H3K4Me3 involved JARID1 histone demethylases, ChIP for 
JARID1A and JARID1B at MLL target gene promoters was performed.   
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C. ChIP for JARID1B at MLL target 
gene promoters 
D. qRT-PCR for JARID1B 
A. ChIP for JARID1A at MLL target gene 
promoters 
B. qRT-PCR for JARID1A 
p = 0.0004 
 
Figure 9: Effect of Cyp33 on the recruitment of H3K4Me3 demethylases JARID1A 
and JARID1B 
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F. ChIP for JARID1B 
at JARID1B promoter 
E. ChIP for JARID1B at House-
keeping gene promoters 
Figure A through F 293T cells were transiently transfected with pCep4 (vector) 
or pCep4-Cyp33 plasmids and harvested after 48 hours for RNA extraction or 
ChIP. A, ChIP for JARID1A at MLL target gene promoters;  B, qRT-PCR for 
JARID1A; C, ChIP for JARID1B at MLL target gene promoters; D, qRT-PCR 
for JARID1B;  E, ChIP for JARID1B at house-keeping gene promoters; F, ChIP 
for JARID1B at JARID1B promoter. n=3, average of 3 independent experiments, 
error bar represent S.D. Figure G and H MSA cells were transiently transfected 
with si RNA for GFP or CYP 33 after 48 hours for RNA extraction or for ChIP. 
G, ChIP for JARID1B at CDKN1B promoter; H, qRT-PCR for CYP33. n=1, the 
error bars are from triplicates from q-PCR. 
G. ChIP for JARID1B at CDKN1B 
promoter 
H. qRT-PCR for CYP33 
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Upon Cyp33 over expression there is an increase in recruitment of JARID1A at the 
promoters of MLL target genes HOXA9 (4.7 fold), HOXC8 (2.7 fold), and CDKN1B (1.8 
fold) (Figure 9A). Also Cyp33 over expression resulted in a pronounced increase on 
JARID1B recruitment at the promoters of MLL target genes HOXA9 (14.5 fold), HOXC8 
(12.2 fold) and CDKN1B (11 fold) (Figure 9C). As shown by qRT-PCR Cyp33 over 
expression did not affect the overall expression of JARID1A and JARID 1B (Figure 9B 
and D). 
To investigate if the Cyp33 mediated increase in recruitment of JARID1B 
occurred specifically at MLL target gene promoters, or also happens at other promoters, 
ChIP for JARID1B at the promoters of house-keeping genes like GAPDH, Histone H4, 
B-globin and RPL10 was performed (Figure 9E). Similar to MLL target genes, over 
expression of Cyp33 resulted in increased recruitment of JARID1B at the promoters of 
house-keeping genes. Since JARID1B expression was unaffected by Cyp33 over 
expression, there should not be increased recruitment of JARID1B at JARID1B promoter 
upon Cyp33 over expression. Hence ChIP for JARID1B at the JARID1B promoter was 
performed (Figure 9F). Cyp33 over expression did not increase the recruitment of 
JARID1B at JARID1B promoter. This shows that Cyp33 mediated increased recruitment 
of JARID1B does not occur globally at all promoters, it occurs at specific promoters, but 
not restricted to MLL-target promoters. The effect of Cyp33 over expression on 
JARID1B recruitment was confirmed by Cyp33 knock down experiment performed by 
Steven Poppen in the laboratory (Figure 9G & 9H). Knock down of Cyp33 resulted in 
decrease in JARID1B recruitment suggesting that JARID1B may be a downstream 
effector of Cyp33 mediated transcriptional regulation. 
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Similar to MLL; both JARID1A and JARID1B have a PHD3. Since Cyp33 RRM is a 
ligand for the MLL PHD3, we wanted to know if the same is true for JARID1A and 
JARID1B PHD3s. Hence a co-immunoprecipitation was performed in 293T cells (Figure 
10).  In contrast to MLL, JARID1B does not interact with Cyp33.  
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Co-Immunoprecipitation for FLAG JARID1B and HA Cyp33 
 
293T cells were transfected with indicated plasmids. After 48 hours cells were 
lysed in IPH lysis buffer. JARID1B was immuno-precipitated using an anti-FLAG 
antibody and immunoblotted for FLAG tagged JARID1B in the1st panel from the 
top, and for HA Cyp33 in the 2
nd
 panel from the top. Third and fourth panels are 
inputs showing the over expression of FLAG tagged JARID1B and HA Cyp33 
respectively. The fifth panel is an immunoblot for actin showing equal amount of 
protein is present in both samples. n=2, a representative experiment is shown. 
 
Figure 10:  Verification of interaction of Cyp33 and JARID1B in vivo 
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Figure 11: Effect of PPIase activity of Cyp33 on H3K4Me3 and H3K27Ac levels and 
JARID1A and JARID1B recruitment at MLL target gene promoters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. ChIP for H3K27Ac and H3K4Me3 at HOXA9 promoter 
 
 
B. ChIP for H3K27Ac and H3K4Me3 at CDKN1B promoter 
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C. ChIP for JARID1A and JARID1B at HOXA9 promoter 
 
D. ChIP for JARID1A and JARID1B at CDKN1B promoter 
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E. qRT-PCR for HOXA9 and CDKN1B 
 
  
F. qRT-PCR for CYP33 
 
 
293T cells were transiently transfected with pCep4 (vector), or plasmids coding for 
pCep4-Cyp33, pCep4-Cyp33 PPIase mutant and harvested after 48 hours for RNA 
extraction and ChIP for H3K4Me3, H3K27Ac, JARID1A and JARID1B followed 
by q-PCR. A, ChIP for H3K4Me3 and H3K27Ac at HOXA9 promoter; B, ChIP for 
H3K4Me3 and H3K27Ac at CDKN1B promoter; C. ChIP for JARID1A and 
JARID1B at HOXA9 promoter; D, ChIP for JARID1A and JARID1B at CDKN1B 
promoter. Rabbit IgG was used as a negative control for the pull-down. n=1, error 
bar represents +/- S.D from the triplicates of q-PCR; E, qRT-PCR for HOXA9 and 
CDKN1B; F, qRT-PCR for CYP33.n=1, error bar represents +/- S.D from the 
triplicates of q-PCR. 
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Experiments performed by Steven Poppen in our laboratory showed that the 
recruitment of transcriptional repressors like HDAC1 and Bmi-1 to the repression domain 
of MLL is PPIase dependent. JARID1A and JARID1B are present in complex with 
HDAC
103–105
. Therefore, we wanted to investigate if the PPIase activity of Cyp33 is 
required for Cyp33 mediated increased recruitment of JARID1A and JARID1B at MLL 
target gene promoters. Over expression of wild type Cyp33 resulted in dramatic increase 
in recruitment of JARID1A and JARID1B at MLL target promoters like HOXA9 and 
CDKN1B when compared to vector control. Nevertheless, over expression of a mutant 
Cyp33 that results in 99% decrease in PPIase activity did not show the increased 
recruitment of JARID1A and JARID1B at MLL target promoters (Figure 11 C and D). 
Also, the PPIase mutant showed increased H3K4Me3 levels and H3K27Ac levels at the 
MLL target gene promoters (Figure 11A and B).  
To determine if JARID1B is a transcriptional repressor of MLL target genes, 
shRNA mediated knock down of JARID1B was performed in 293T cells and the effect 
on the transcription of MLL target genes was measured by qRT-PCR (Figure 12A). The 
knock down of JARID1B was verified by qRT-PCR (Figure 12B). About 50% decrease 
in the mRNA levels of JARID1B was achieved by shRNA. JARID1B knock down 
resulted in about two-fold increase in HOXA9 and about 3.2 fold increase in CDKN1B 
transcription, whereas there was no effect on the transcription of other MLL target genes 
like Myc and Meis1. Thus JARID1B knock down affected the transcription of a sub-set of 
MLL target genes. The striking increase in JARID1B recruitment and a concomitant  
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A. qRT-PCR for MLL target genes                  B. qRT-PCR for JARID1B 
 
 
p = 0.0058 
p = 0.0029 
p = 0.0167 
p = 0.055 
293T cells were stably transfected with plasmids for control shRNA or shRNA 
against JARID1B. Stable transfectants were selected in puromycin for 5 days. Cells 
were harvested for RNA extraction followed by q RT-PCR for A, MLL target genes; 
B, for JARID1B. n=3, average of 3 independent experiments and error bar represents 
S.D. p values are from two-tailed unpaired t-test.  
p = 0.0024 
 
 Figure 12: Effect of knock down of JARID1B at MLL target genes 
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decrease in H3K4Me3 levels at MLL target gene promoters upon Cyp33 over expression, 
suggested that JARID1B may be one of the downstream effectors of Cyp33.  
To know if JARID1B mediates Cyp33 transcription regulation of MLL target 
genes, Cyp33 was transiently over expressed in cells that have shRNA mediated stable 
knock down of JARID1B. pCep4 transfection after JARID1B knockdown resulted in 
statistically significant increase in expression of HOXA9 (Figure 13A) and CDKN1B 
(Figure 13B) when compared to pCep4-Cyp33 transfection in sh control cells. This again 
shows that JARID1B is a transcriptional repressor of MLL target genes. Cyp33 over 
expression in sh control transfected cells resulted in a statistically significant decrease in 
transcription of HOXA9 and CDKN1B when compared to sh control cells transfected with 
pCep4. This also reiterates that Cyp33 is a transcriptional repressor of MLL target genes. 
If JARID1B is a downstream effector of Cyp33 mediating transcriptional repression of 
MLL target genes, over expressing Cyp33 in the absence of JARID1B should not result 
in transcriptional repression of MLL target genes. However, Cyp33 over expression in 
JARID1B knock down cells resulted in statistically significant transcriptional repression 
of HOX A9 and CDKN1B when compared to sh control cells that over express Cyp33 
(Figure 13A and 13B). Hence, reducing the levels of JARID1B did not overcome Cyp33 
mediated transcriptional repression of MLL target genes. Thus, even if JARID1B is a 
transcriptional repressor of MLL target genes; it may not be the only downstream effector 
of Cyp33. Over expression of Cyp33 and knock down of JARID1B was verified by qRT-
PCR for CYP33 and JARID1B (Figure 13C and 13D).  
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A. qRT-PCR for HOXA9 
 
 
B. qRT-PCR for CDKN1B 
 
 
 
n.s 
n.s 
 
 
Figure 13: Effect of knock down of JARID1B and over expression of Cyp33 on 
the transcription of MLL target genes 
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C. qRT-PCR for JARID1B 
 
D. qRT-PCR for CYP33 
 
293T cells were stably transfected plasmids for control shRNA or shRNA against 
JARID1B. Stable transfectants were selected in puromycin for 5 days. Further cells were 
transfected with pCep4 (vector) or pCep4-Cyp33 plasmids. After 48 hours, cells were 
harvested for RNA extraction followed by qRT-PCR for: A, HOXA9; B, CDKN1B; C, 
JARID1B; and D, Cyp33. n=2, average of 2 independent experiments and error bar 
represents S.D. n.s means not statistically significant. 
 
 
p = 0.0005 
p = 0.0027 
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Aim 2: Determine the significance of MLL PHD3 binding to H3K4Me3 vs Cyp33. 
In addition to binding to Cyp33, the MLL PHD3 also binds to H3K4Me3. This 
binding was reported by us and other groups 
26,29,30
. All these studies focused on the in 
vitro interactions of MLL PHD3 or Cyp33. Hence the biological significance of 
H3K4Me3 binding and Cyp33 binding to the MLL PHD3 is yet to be determined. From 
all these studies we know which are the amino acids in the MLL PHD3 finger that 
contribute to H3K4Me3 binding and Cyp33 binding. Conserved aromatic and 
hydrophobic residues in the PHD3 of MLL form a cage that acts as a binding pocket for 
H3K4Me3 
26,29,30
. Chang et al. have shown that the M1585A mutation abrogates 
H3K4Me3 binding and resulted in decreased transcriptional activation of MLL target 
genes. Unlike the W1594A point mutant, this mutation did not affect the protein stability 
30
.  Based on this information, we mutated methionine 1585 to alanine (M1585A) as a 
candidate mutation to disrupt the binding to H3K4Me3. Wang et al. have shown that 
mutating methionine 1606 to aspartate in MLL abolished the binding of MLL PHD3 to 
Cyp33 
29
. Moreover, methionine 1606 does not participate in H3K4Me3 binding. Hence 
M1606D mutation should not interfere with H3K4Me3 binding and was used as a 
candidate mutation that disrupts MLL PHD3 binding to Cyp33. 
MLL is required for normal hematopoiesis 
6,7,67,106
. In order to understand the 
biological significance of MLL PHD3 binding to H3K4Me3 versus Cyp33, we wanted to 
study the effect of the mutations in the context of a full length MLL protein in 
hematopoietic progenitor colony formation assay. But MLL is a big protein and the 
cDNA is about 14KB long. Therefore, it will be difficult to mutate, clone and will be 
impossible to package such a big construct in retro viruses.  MLL is proteolytically 
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cleaved into MLL-N and MLL-C; the fragments interact with each other through their 
FYRN and FYRC domains, and MLL-C stabilizes MLL-N 
36,37,74
. The N-fragment has 
the PHD3 finger that binds to H3K4Me3 and the C-fragment has the H3K4Me3 methyl 
transferase activity. To circumvent the practical problems of expressing a big construct, 
the mutations were made in a DNA sequence encoding the MLL-N fragment instead of 
full length MLL. FLAG tagged MLL-N from the pCI-MLL-N provided by Dr. James 
Hsieh was cloned into MSCV neo by Wei Wei in our laboratory. MSCV neo FLAG 
MLL-N M185A and M1606D were generated in this study by site-directed mutagenesis 
in a smaller fragment of MLL-N, and swapped into MSCV MLL-N wt as explained in the 
Methods section.  
To date, the interaction of the MLL PHD3 with H3K4Me3 has been only 
demonstrated in vitro. To determine if MLL-N wt (which has the PHD3) binds to 
H3K4Me3 in vivo, a nucleosome pull down assay was performed. If MLL-N (through its 
PHD3) binds to H3K4Me3, then it would co-immunoprecipitate with nucleosomes that 
are trimethylated at H3K4. Partial digestion of the chromatin fraction with micrococcal 
nuclease will result in induction of double stranded breaks of DNA in the nucleosome 
linker region, releasing mononucleosomes. Enrichment for the mononuclesome fraction 
was optimized by varying the time and temperature of digestion. To standardize the 
micrococcal nuclease assay, chromatin was isolated from 293T cells as explained in 
methods section and the micrococcal nuclease digestion was performed at the indicated 
time and temperature (Figure 14B). About 146 bp of DNA are wound around a 
mononucleosome. To verify mononucleosome enrichment, the DNA was purified from 
proteins and loaded onto a 2% agarose gel containing ethidium bromide. DNA fractions, 
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with an average length of about 150 bp were obtained by performing the digestion at 
37°C for 4 minutes and 30 seconds (Figure 14B).  
A nucleosome Co-IP of FLAG MLL-N and H3K4Me3 was performed (Figure 
14C). FLAG MLL-N co-immunoprecipitated with trimethylated H3K4, whereas the 
vector control did not. This shows that there is no non-specific binding of the 
nucleosomes to the protein A conjugated FLAG beads. To ensure that there is equal 
amount of H3K4Me3 containing nucleosomes present in the nucleosome preparations, a 
Western blot for H3K4Me3 was performed (Figure 14C). After establishing the 
conditions of the nucleosome Co-IP with MLL-N wt, the binding status of M1585A and 
M1606D mutants to H3K4Me3 was determined using the same assay. The micrococcal 
digestion and the release of mononucleosomes were verified (Figure 15B). A nucleosome 
Co-IP of FLAG MLL-N or the mutants with H3K4Me3 performed (Figure 15C) showed 
that both MLL-N wt and the M1606D mutant co-immunoprecipitated with nucleosomes 
containing H3K4Me3. In contrast, the M1585A mutant behaved similar to that of the 
vector control (negative control). Hence a M1585A mutation in the PHD3 of MLL-N 
abrogates binding to H3K4Me3 marked nucleosomes.  
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A,  Schematic of Nucleosome pull-down assay; B, Standardization of microcoocal 
nuclease digestion was performed in untransfected 293T cells. Enrichment for 
mononucleosomes was verified by agarose gel, n=1; C, Nucleosome Co-ip, 293T cells 
were transiently transfected with FLAG MLL-N wt, cells or MSCV neo (Vector) 
plasmids. Cells were harvested after 48 hrs for micrococcal digestions at 37C for 4 min 
30” followed by nucleosome pull down assay. FLAG tagged MLL-N was 
immunoprecipitated with anti-FLAG agarose beads and immunoblotted for H3K4 
trimethylated nucleosomes with anti H3K4Me3 antibody, n=2, a representative 
experiment is shown. 
 
 
 
Figure 14: Verification of binding of MLL-N wt to H3K4Me3 nucleosomes in vivo 
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293T cells were transfected with MSCV neo (E) or FLAG tagged MLL-N wt (wt), 
M1585A (MA), M1606D (MD) plasmids. Cells were harvested after 48 hrs for a 
nucleosome pull down assay: A, Schematic of binding of MLL-N wt and mutants to 
H3K4Me3 and Cyp33; B, Micrococcal nuclease digestion performed to enrich for 
mononucleosomes which was verified by DNA agarose gel, (MW means DNA 
molecular weight marker); C, Nucleosome Co-IP Nucleosome Co-IP: FLAG tagged 
MLL-N was immunoprecipitated with anti-FLAG agarose beads and immunoblotted for 
H3K4 trimethylated nucleosomes with anti H3K4Me3 antibody. MW means n=2, a 
representative experiment is shown.  
 
 
 Figure 15: Binding status of M1585A and M1606D to H3K4Me3 nucleosomes in vivo 
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The binding status of MLL-N wt, or the mutants, to Cyp33 was determined using 
a GST pull down experiment, by Dr. Osmers in our laboratory. As expected the MLL-N 
wt and M1585A mutant both bind Cyp33, but the M1606D mutation does not. 
H3K4Me3 is a transcriptional activation mark. Hence, MLL PHD3 binding to 
H3K4Me3 may protect H3K4Me3 from being targeted by histone demethylases. 
Furthermore, MLL is a writer of H3K4Me3 marks. Hence, MLL PHD3 binding to 
H3K4Me3 may help MLL-C in the propagation of methyl marks to adjacent 
nucleosomes. Both these scenarios should result in an increase in H3K4Me3 marks at 
MLL target gene promoters. As a consequence, MLL PHD3 binding to H3K4Me3 should 
result in transcriptional activation of MLL target genes and abrogating the binding should 
result in decrease in transcription of MLL target genes.  
From in vitro binding studies, it is known that Cyp33 has a higher affinity for 
MLL PHD3 than H3K4Me3 and Cyp33 in excess reduces the affinity of MLL PHD3 for 
H3K4Me3 
26
. Cyp33 over expression in our studies also resulted in a decrease of 
H3K4Me3 marks and increased recruitment of JARID1B histone demethylases at MLL 
target gene promoters. Hence abrogating Cyp33 binding in MLL PHD3 should reduce the 
exposure of H3K4Me3 to the JARID1B histone demethylase, resulting in an increase in 
H3K4Me3 marks and increase in transcription of MLL target genes. In short, the 
hypothesis of the second aim of this study is that MLL PHD3 binding to H3K4Me3 
contributes to transcriptional activation, while MLL PHD3 binding to Cyp33 contributes 
to transcriptional repression of MLL target genes. 
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A. qRT-PCR for MLL 
 
 
B. Western Blot for FLAG tagged MLL-N and Mutants 
 
 
MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or 
M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11 
days. Cells were harvested for RNA followed by: A, qRT-PCR for human MLL. n=3, 
average of 3 independent experiments; B, Immunoblot for FLAG tagged MLL-N and 
mutants. n=2, a representative experiment is shown. 
 
Figure 16: Verification of over expression of MLL-N 
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To test the above mentioned hypothesis, MEF (Mll+/+) were transduced with 
MSCV neo (Vector), MLL-N wt., M1585A or M1606D expressing retro-viruses and the 
effect on target gene expression was assessed by qRT-PCR. Over expression of MLL-N 
wt and mutants was verified by qRT-PCR (Figure 16A). MLL transcripts were 
normalized to Actb transcripts levels. There is about the same level of over expression of 
MLL-N wt and mutants. Over expression of MLL-N at the protein level was verified by 
immunoblot for FLAG tag (Figure 16B).  
 The effect of over expression of MLL-N wt and mutant on target gene expression 
was measured by qRT-PCR (Figure 17). Over expression of MLL-N wt resulted in a 
statistically significant increase in transcription of the MLL target genes like Hoxa9, 
Hoxc8, and Cdkn1b when compared to the vector control. The p values from one sample 
Student’s t test when compared between vector and MLL-N wt for Hoxa9, Hoxc8 and 
Cdkn1b are 0.0068, 0.0097, and 0.0087 respectively. Over expression of M1606D mutant 
(that does not bind Cyp33) resulted in transcriptional activation of Hoxa9, Hoxc8 and 
Cdkn1b, a trend similar to that of MLL-N wt over expression. However, the p values 
from one sample student’s t test when compared between vector and M1606D for Hoxa9, 
Hoxc8 and Cdkn1b are 0.0646, 0.0204 and 0.0495 showed that the statistically significant 
transcriptional activation was observed only for Hoxc8 and Cdkn1b but not for Hoxa9. 
Additionally, the M1606D mutation did not result in increased transcription of MLL 
target genes over the MLL-N wt over expression.  
In contrast to MLL-N wt and M1606D mutant, over expression of MLL-N 
M1585A (that does not bind H3K4Me3) did not have any effect on transcription of MLL 
target genes when compared to the vector control. However, M1585A over expression 
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resulted in a decrease in transcription of MLL target genes when compared to MLL-N wt 
and its M1606D mutant. The p values from two-tailed unpaired student’s t-test compared 
between M1585A and MLL-N wt for Hoxa9, Hoxc8 and Cdkn1b are 0.0063, 0.0025 and 
0.0037 respectively. The p values from two-tailed unpaired student’s t-test compared 
between M1585A and M1606D for Hoxa9, Hoxc8 and Cdkn1b are 0.0352, 0.012 and 
0.0094 respectively. This shows that MLL PHD3 binding to H3K4Me3 contributes to the 
transcriptional activation of MLL target genes.  
Since MLL-N wt over expression resulted in transcriptional activation of MLL 
target genes, I hypothesized that MLL-N over expression resulted in increased protein 
stability of MLL-C or nuclear import of MLL-C. To test this, MEFs were transduced with 
MSCV neo (vector), or MLL-N wt, M1585A and M1606D retro-viral expression 
constructs and cells were harvested for nuclear lysate preparation. Further, a Western blot 
for MLL-C (Figure 18A) showed that MLL-N wt over expression did not increase MLL-
C protein levels. Alternatively, I hypothesized that MLL-N wt over expression increased 
the recruitment of MLL-C at MLL target gene promoters, thus leading to increase in 
transcription of MLL target genes. Hence a ChIP for MLL-C at the Hoxa9 promoter was 
performed in (Figure 18B). MLL-N wt over expression resulted in a statistically 
significant increase in MLL-C recruitment at the Hoxa9 promoter when compared to the 
vector control (one sample student’s t-test p = 0.031), M1585A (unpaired student’s t- test 
p = 0.0017 and M1606D (unpaired student’s t- test p = 0.0322).  However there is no 
increase in MLL-C recruitment upon MLL-N wt over expression at the house-keeping 
gene promoter, Actb promoter (Figure 18C). Unlike MLL-N wt over expression, 
M1585A over expression did not result in increase in MLL-C recruitment at the Hoxa9   
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                          qRT-PCR for MLL target genes 
 
MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or 
M1606D retroviruses (in the presence of endogenous MLLC) and selected with G-
418 for 11 days. Cells were harvested for RNA preparation followed by quantitative 
RT-PCR for MLL target genes. n=3, average of 3 independent experiments, error bars 
represent S.D.  Pairwise comparisons between M1585A and MLL-Nwt ; M1585A and 
M1606D were performed by two-tailed unpaired Student’s t-test. ** - Decrease in 
transcription of MLL target genes in M1585A is statistically significant when 
compared to MLL-N wt (Hoxa9- p = 0.0063, Hoxc8- p = 0.0025, Cdkn1b- p = 0.037) 
and M1606D (Hoxa9- p = 0.0352, Hoxc8- p = 0.012, Cdkn1b- p = 0.0094).   
 
Figure 17: Effect of MLL-N wt and mutants over expression on transcription of 
MLL target genes 
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Figure 18: Effect of MLL-N and mutant over expression on MLL-C recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Western Blot for MLL-C                     Loading Control 
 
 
B. ChIP for MLL-C at Hoxa9 promoter           C. ChIP for MLL-C at Actb promoter 
 
MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or 
M1606D retroviruses (in the presence of endogenous MLLC) and selected with G-418 for 
11 days. Cells were harvested for: A, Immunoblot for MLL-C, Cells were lysed for nuclear 
lysate preparation, followed by immunoblot for MLL-C, n=1; B, ChIP for MLL-C at the 
Hoxa9 promoter. Pairwise comparisons were performed by either one sample or unpaired 
two-tailed student’s t-tests. * means increase in MLL-C recruitment in MLL-N wt when 
compared to vector (one sample student’s t test p = 0.031) and M1585A (unpaired student’s 
t- test p = 0.0017). ** means decrease in MLL-C recruitment in M1606D when compared to 
MLL-N wt (unpaired student’s t- test p = 0.0322) and to M1585A (unpaired student’s t- test 
p = 0.0011). C, ChIP for MLL-C at Actb promoter. n=3, average of 3 independent 
experiments, error bar represents S.D.   
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promoter when compared to vector control. The p value from one sample student’s t-test 
performed between vector control and MLL-N wt is 0.1421. This shows that MLL PHD3 
binding to H3K4Me3 may be involved in the recruitment of MLL-C to Hoxa9 promoter.  
Surprisingly, the M1606D mutant (that does not bind Cyp33) showed a decrease in 
recruitment of MLL-C at the Hoxa9 promoter when compared to, M1585A (unpaired 
student’s t- test p = 0.0011) and MLL-N wt (unpaired student’s t- test p = 0.0322). 
Since over expression of MLL-N wt and M1606D mutant resulted in 
transcriptional activation of MLL target genes but M1585A did not, we hypothesized that 
MLL PHD3 binding to H3K4Me3 contributes to transcriptional activation of MLL target 
genes. This may be because, MLL PHD3 binding to H3K4Me3 protects H3K4Me3 from 
being demethylated by histone demethylases and/or helps in propagation of methyl marks 
to adjacent nucleosomes. Both the above mentioned scenarios should result in increased 
H3K4Me3 at MLL target genes resulting in increased transcriptional activation of MLL 
target genes. To calculate the fold enrichment for H3K4Me3 at a given promoter, the 
amount of H3 present at a given promoter should be determined. A ChIP for histone H3 
at MLL target genes was performed (Figure 20A). MLL-N wt and mutant over 
expression did not significantly affect the total H3 levels both at MLL target genes and 
Actb promoter (Figure 19 A & B).  
After determining the histone H3 density at MLL target genes, a ChIP for 
H3K4Me3 at MLL target gene promoters was performed (Figure 20A). Over expression 
of MLL-N wt resulted in an increase in H3K4Me3 marks relative to vector control at the 
Hoxa9 promoter, but did not show a statistically significant increase at the Cdkn1b 
promoter. The p values from one sample student’s t-test are 0.0067 and 0.1187 
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respectively. Over expression of MLL-N wt also resulted in a statistically significant 
increase relative to the M1585A mutant in H3K4Me3 marks at the Hoxa9 (unpaired 
student’s t-test p =0.001) and Cdkn1b (unpaired student’s t-test p =0141) promoters but 
not at the Actb promoter (Figure 20B). Abrogating H3K4Me3 binding resulted in a 
decrease in H3K4Me3 marks, a decrease in MLL-C recruitment and decrease in target 
gene expression. These results together suggest that MLL PHD3 binding to H3K4Me3, 
helps MLL-C to methylate adjacent nucleosomes. The M1606D mutant did not show a 
significant increase in H3K4Me3 marks over the vector control and the M1585A mutant. 
This may be a result of decreased recruitment of MLL-C at the MLL target promoters 
(Figure 20A). 
  Next, to determine if MLL PHD3 binding to H3K4Me3 protects H3K4Me3 from 
histone demethylases, MLL-N wt or its mutants were over expressed, and recruitment of 
the JARID1B histone demethylase at the MLL target gene promoters was measured by 
ChIP. If MLL PHD3 binding to H3K4Me3 protects H3K4Me3 from histone 
demethylases, then abrogating MLL PHD3 binding to H3K4Me3 should result in 
increased recruitment of JARID1 histone demethylases at MLL target gene promoters. 
There was no significant difference between vector control, MLL-N wt and M1585A in 
the recruitment of JARID1B at Hoxa9 promoter (Figure 21A). This shows that in the 
system used, MLL PHD3 binding to H3K4Me3 does not protect H3K4Me3 from 
JARID1B binding.  M1606D over expression resulted in a statistically significant 
decrease in the recruitment of JARID1B at the Hoxa9 promoter when compared to the 
vector control (one sample t-test p = 0.0046, MLL-N wt (unpaired student’s t-test p = 
0.034) or M1585A (unpaired student’s t-test p = 0.0351).   
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Figure 19: Effect of over expression of MLL-N wt and mutants on histone H3 
density 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A. ChIP for Histone H3 at MLL target gene promoters. 
 
B. ChIP for Histone H3 at Actb promoter. 
 
 
MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or 
M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11 days and 
harvested for ChIP for histone H3 at: A, MLL target gene promoters, B, Actb promoter 
was performed. n=3, average of 3 independent experiments, error bars represent S.D. 
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Figure 20: Effect of over expression of MLL-N wt and mutants on H3K4Me3 marks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. ChIP for H3K4Me3 at MLL target gene promoters 
 
 B. ChIP for H3K4Me3 at Actb promoter. 
 
MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A 
or M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11 
days and harvested for ChIP for histone H3K4Me3 at A, MLL target gene promoters, 
B, Actb promoter in figure B was performed. n=3, average of 3 independent 
experiments, error bars represent S.D.  * Decrease in H3K4Me3 levels in M1585A at 
the Hoxa9 (unpaired student’s t-test p =0.001) and Cdkn1b (unpaired student’s t-test 
p =0141) when compared to MLL-N wt. 
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Figure 21: Effect of over expression of MLL-N wt and mutants on JARID1B 
recruitment  
 
A. ChIP for JARID1B at Hoxa9 promoter   B.  ChIP for JARID1B at Actb 
promoter    
 
 
MEFs (MLL +/+) were transduced with MSCV neo (Vector), MLL-N wt, M1585A or 
M1606D (in the presence of endogenous MLLC) and selected with G-418 for 11 days 
and harvested for ChIP for: A, JARID1B at MLL target gene promoters.  *- Decrease in 
JARID1B recruitment when compared to vector control (one sample t-test p = 0.0046) 
MLL-N wt- p = 0.034 and M1585A- p = 0.0351; B, JARID1B at Actb promoter. n=3, 
average of 3 independent experiments, error bars represent S.D. 
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Figure 22: Verification of over expression of MLL-N wt and mutants in mouse 
hematopoietic progenitors 
 
          qRT-PCR for MLL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
C kit + mouse hematopoietic progenitors isolated from mouse bone marrow were retro 
virally transduced with MSCV neo (Vector), MLL-N wt, M1585A, and M1606D and 
grown in RPMI containing IL-3, IL-6, SCF, GM-CSF and selected with G418 for 3 days. 
The cells were harvested for RNA extraction followed by qRT-PCR for human MLL. 
n=3, average of 3 independent experiments, error bars represent S.D. 
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Figure 23: Effect of over expression of MLL-N wt and mutants on MLL target gene 
expression in Ckit+ve mouse hematopoietic progenitors 
  
 
Transduction and selection as explained in Figure. Cells were harvested for RNA 
extraction. qRT-PCR for MLL target genes was performed. *- Statistically 
significant decrease in expression of Hoxa9 and Meis1 in Vector and M1585A when 
compared to MLL-N wt over expression. ** Statistically significant increase in 
expression of Cdkn1b and Cdkn1a in M1585A when compared to Vector, M1585A 
and M1606D. n=3, average of 3 independent experiments, error bars represent S.D.  
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Hence, abrogating MLL PHD3 binding to Cyp33 (M1606D) resulted in decreased 
recruitment of histone demethylases at MLL target gene promoters whereas at the Actb 
promoter there was no significant decrease. 
Since over expression of MLL-N wt or mutants had an effect on MLL target 
genes in MEFs, I wanted to determine the effect of over expression of MLL-N wt and its 
mutants in mouse hematopoietic progenitors. Over expression of MLL-N wt, its mutants 
M1585A and M1606D in C-kit+ mouse hematopoietic progenitors after retro viral 
transduction was verified by qRT-PCR for human MLL normalized to Actb. The data in 
Figure 23 shows that MLL-N wt, M1585A and M1606D are expressed at about equal 
levels in hematopoietic progenitors.  
Having confirmed that the retro-viral transductions have worked in hematopoietic 
progenitors the effect of over expression of MLL-N wt and mutants on target gene 
expression was assessed by qRT-PCR (Figure 23). Similar to MEF, over expression of 
MLL-N wt and M1606D in hematopoietic progenitors resulted in statistically significant 
increase in expression of Hoxa9 when compared to vector and M1585A. The p value, 
from Student’s t-test, when comparing between MLL-N wt and M1585A over expression 
is 0.0056. The p value for M1606D and M1585A is 0.0243. Over expression of MLL-N 
wt and M1606D also resulted in increased transcription of Meis1 when compared to 
vector and M1585A. This shows that MLL PHD3 binding to H3K4Me3 in hematopoietic 
progenitors contributes to transcriptional activation of MLL target genes. 
Like Hoxa9 and Meis1, Cdkn1a and Cdkn1b are known targets of MLL 
10,11
. In 
contrast to Hoxa9 and Meis1, over expression of MLL-N wt did not increase the 
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transcription of Cdkn1b and Cdkn1a. Whereas the over expression of M1585A resulted in 
increased expression of Cdk1b and Cdkn1a. The expression of Pu.1 remained unaffected 
by MLL-N and mutant over expression. Hoxa9 and Meis1 expression keeps the 
hematopoietic progenitors in an undifferentiated state. Upon differentiation their 
expression decreases. Since MLL PHD3 binding to H3K4Me3 contributes to 
transcriptional activation of Hoxa9 and Meis1, we tested the effects of MLL-N wt on 
hematopoiesis using an in vitro colony formation assay. If the cells are in undifferentiated 
state, each progenitor would undergo multiple cell divisions giving rise to a colony in 
methyl cellulose. This assay is a measure of the proliferation potential of hematopoietic 
progenitors. A portion of transduced Ckit+ mouse hematopoietic progenitors used in the 
previous experiment (Figure 23) were plated on methyl cellulose containing IL-3, IL-6, 
GM-CSF and SCF. The successful transduction and over expression of MLL-wt and 
mutants was verified (Figure 22). When compared to vector control transduced cells, 
MLL-N over expression resulted in a decrease in colony formation. Considering the fact 
that the MSCV neo MLL-N retroviral expression construct is at least twice longer than 
the MSCV neo vector, the differences in the viral titer and expression of neo-resistance 
will affect the colony formation. Since MLL-N wt, M1585A and M1606D are the same 
molecular weight and they have about equal levels of expression, I compared the colony 
formation potential of MLL-N wt to that of the mutants. M185A over expression resulted 
in a drastic reduction in colony formation when compared to MLL-N wt and vector 
control (Figure 24); over expression of the M1606D mutant showed no difference with 
MLL-N wt. Hence MLL PHD3 binding to H3K4Me3 contributes to MLL’s function in 
hematopoiesis.  
 91 
 
 
 
Figure 24: Effect of over expression of MLL-Nwt and mutants on the colony 
formation potential of hematopoietic progenitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                             Hematopoietic Progenitors Colony Formation Assay. 
  
 
 
Ckit+ve selection and transduction as explained in Figure. Transduced cells were 
selected with G418 on a methyl cellulose plate containing IL-3, IL-6, SCF, and GM-
CSF for 7 days. Colonies were counted on Day7. n=3, average of 3 independent 
experiments, error bar represents S.D. Pairwise comparisons were performed by 
n.s 
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Figure 25: Effect of MLL-N wt and mutants over expression on colony formation of 
MLL-AF9 transformed hematopoietic progenitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Hematopoietic Progenitor Colony Formation Assay. 
  
 
 
C-kit+ve hematopoietic progenitors were isolated from mouse bone marrow, 
transduced with MSCV puro MLL-AF9 retoviruses, selected for a week in 
puromycin and grown in RPMI containing IL-3, IL-6, SCF and GM-CSF . 
Further, cells were transduced with MSCV neo (Vector), MLL-N wt, M1585A or 
M1606D retroviruses and plated on methyl cellulose containing G418, IL-3, IL-
6, SCF, and GM-CSF. Colonies were counted on Day7. The cells were recovered 
and re-plated on methyl cellulose. The figure above is from week3 re-plating. 
Representative colony images are shown. n=2, average of two independent 
experiments, error bar represents S.D.  
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The results from this study revealed that MLL PHD3 binding to H3K4Me3 
contributes to transcriptional activation of genes that regulate hematopoiesis. Recent 
studies showed that the MLL wt allele is required for MLL-fusion mediated 
leukemogenesis 
20,40
. The MLL-fusion protein lacks the 3
rd
 PHD finger. But the MLL wt 
allele has the PHD3 intact. To know if MLL PHD3 (present in MLL wt) binding to 
H3K4Me3 contributes to MLL fusion mediated leukemogenesis, the effect of 
overexpression of MLL-N wt and the mutants on colony formation by MLL-AF9 
transformed hematopoietic progenitors was tested (Figure 25). Over expression of MLL-
N or the mutants did not affect the colony formation of MLL-AF9 transformed 
hematopoietic progenitors in the assay conditions tested. 
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CHAPTER 5 
DISCUSSION 
Many chromatin associated proteins have tandem PHD fingers that mediate DNA 
binding, histone binding or serve as domains for other protein-protein interactions. MLL 
has 3 tandem PHD fingers. More than a decade ago, studies from our lab identified 
Cyp33 as a ligand for MLL PHD3. Cyp33 over expression resulted in transcriptional 
repression of MLL target genes 
23,57
. Thus Cyp33 over expression switches MLL from a 
transcriptional activator to a repressor. Recently we, and two other groups reported that 
the MLL PHD3 binds to trimethylated H3K4 (H3K4Me3) 
26,29,30
. Since H3K4Me3 is a 
transcriptional activation mark, we hypothesized that binding of MLL PHD3 to 
H3K4Me3 protects it from histone demethylases which would result in transcriptional 
activation of MLL target genes. Thus the PHD3, a small 60 amino acids long region of 
MLL can potentially act as a molecular switch in regulation of transcription of its target 
genes.  
In vitro binding studies performed by our collaborator Dr. Bushweller, showed 
that when Cyp33 is in excess, it reduces the affinity of the MLL PHD3 for H3K4Me3 
26
. 
To determine if this is true in vivo, I sought to test the effect of Cyp33 over expression in 
293T cells on H3K4Me3 methylation and binding of histone demethylases to MLL target 
gene promoters. Previous studies employed a semi- quantitative approach to measure 
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gene expression 
23
, while this study employs qRT-PCR, a quantitative method to measure 
gene expression. Since a different technique was used than in previous studies, before 
doing ChIP for H3K4Me3, the effect of Cyp33 over expression on transcription of MLL 
target genes was first confirmed. We confirmed that Cyp33 over expression resulted in a 
decrease in transcription of MLL target genes. However, the effect of Cyp33 over 
expression on transcription is not exclusive of MLL target genes. Except for β2M, other 
house-keeping genes, which are not MLL target genes, also showed transcriptional 
repression upon Cyp33 over expression. Recently, Steven Poppen from our lab has 
shown that both over expression and knock down of Cyp33 resulted in slow growth of 
cells in culture. This suggests that altering the levels of Cyp33 in the cell may have an 
effect on general metabolism of the cell. Besides, binding to MLL PHD3, Cyp33 is 
known to be present in the spliceosome complex 
107
. Hence the effect of Cyp33 over 
expression on transcription of house-keeping genes may be MLL dependent or MLL 
independent. 
Having confirmed that Cyp33 over expression resulted in decreased expression of 
MLL target genes, I wanted to determine the effect of excess of Cyp33 on H3 density, 
transcriptional activation and repressive histone marks. H3 density reflects the closed or 
open status of the chromatin for access to the RNA POLII transcriptional machinery. 
Cyp33 over expression resulted in increased H3density at MLL target gene promoters, 
which indicates a closed chromatin state and is consistent with the transcriptional 
repression of target genes. One of the possible mechanisms of Cyp33 mediated 
transcriptional repression of MLL target genes, is through increased recruitment of co-
repressors like HDAC1 and Bmi-1 to the repression domain of MLL 
27
. Results from this 
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study show that Cyp33 over expression results in a decrease in H3 acetylation marks 
which can be explained by the increased recruitment of HDAC to the repression domain 
of MLL.  
Like H3Ac, increased H3K4Me3 at the promoter region is linked to 
transcriptional activation. As mentioned earlier, from in vitro binding studies, it is known 
that when Cyp33 is in excess, it reduces the affinity of the MLL PHD3 for the H3K4Me3 
histone mark 
26
. In vivo the scenario is more complicated.  The 3
rd
 PHD finger of the 
JARID1A and JARID1B histone demethylases is also known to bind H3K4Me3 
35,101
. 
The reduced affinity of the MLL PHD3 for H3K4Me3 after binding of Cyp33 may allow 
histone demethylases or other competing ligands to bind this histone mark.  According to 
this hypothesis, Cyp33 over expression should result in increased recruitment of 
JARID1A and JARID1B histone demethylases and consequent decrease in H3K4Me3 
marks. Results from our ChIP experiment showed that Cyp33 over expression resulted in 
increased recruitment of JARID1A and JARDI1B and a corresponding decrease in 
H3K4Me3 marks at MLL target gene promoters which is in agreement with our 
hypothesis.   
Concordant with its effects on the transcription of house-keeping genes, Cyp33 
over expression also resulted in increased recruitment of JARID1B at house-keeping 
gene promoters. However, Cyp33 over expression did not affect the transcription of 
JARID1A and JARID1B nor did it increase the recruitment of JARID1B at the JARID1B 
promoter. This suggests that the effect of Cyp33 over expression on transcription may not 
be a global phenomenon and occurs at a subset of genes. Knock down of Cyp33 in an 
experiment performed in collaboration with Steven Poppen showed a significant decrease 
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in JARID1B recruitment at MLL target gene promoters which is the opposite of what we 
observe when over expressing Cyp33.   
Cyp33 when present in excess, besides exposing the methyl marks to JARID1 
histone demethylases, can also increase the recruitment of JARID1 histone demethylases 
at MLL target genes by other mechanisms. When compared to JARID1A, JARID1B 
recruitment is more pronounced upon Cyp33 over expression. JARID1B directly interacts 
with Class I and Class II HDACs and with hPC2 
105,108
, but there are no studies so far 
showing a direct interaction of JARID1A with HDAC and hPC2. As mentioned earlier, 
Cyp33 over expression, augments the recruitment of transcriptional co-repressors like, 
HDAC1 and Bmi1 to the repression domain of MLL 
27
.  It is certainly a possibility that 
along with other co-repressors Cyp33 may also bring in JARID1B to the repression 
domain of MLL. 
Another mechanism by which Cyp33 can increase the recruitment of JARID1A 
and JARID1B at MLL target promoters is through directly binding to JARID1A and 
JARID1B. Besides the PHD finger of MLL, PHD fingers present in other proteins are not 
known to bind Cyp33.  JARID1A and JARID1B have 3 PHD fingers. Results from this 
study shows that Cyp33 does not co-immunoprecipitate with JARID1B. 
           Cyp33 is a prolyl isomerase, inhibiting the prolyl isomerase activity by 
Cyclosporin A, deleting the Cyclophilin domain that encodes for the PPIase, or over 
expressing a prolyl isomerase deficient mutant of Cyp33, does not result in 
transcriptional repression of MLL target genes 
23,26
. This shows that the PPIase activity of 
Cyp33 is required for the transcriptional repression of MLL target genes. Additionally, 
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the PPIase activity is required for the recruitment of transcriptional repressors like 
HDAC1 and Bmi1 to the repression domain of MLL. Like HDAC1 and Bmi-1, 
JARID1A and JARID1B are transcriptional repressors and are present in complex with 
HDAC. The results from this study show that recruitment of JARID1A and JARID1B is 
PPIase dependent. Furthermore, over expression of the PPIase mutant results in decrease 
in H3K4Me3 levels and H3K27Ac levels at MLL target gene promoters. Though we 
were not able to pin point the exact mechanism of Cyp33 mediated increased recruitment 
of JARID1A and JARID1B to the chromatin, we have identified the requirement of 
PPIase activity of Cyp33 for JARID1A and JARID1B recruitment at MLL target gene 
promoters. 
Since Cyp33 over expression studies suggested a role for JARID1B in 
transcriptional regulation of MLL target genes, shRNA knock down of JARID1B was 
performed in 293T cells. Knock down of JARID1B resulted in increased expression of 
HOXA9 and CDKN1B, indicating that JARID1B is a transcriptional repressor of a sub-set 
of MLL target genes. Only 50% reduction in JARID1B expression was achieved by our 
knock down. If the efficiency of the knock down was improved, there may be an effect 
on the expression of other MLL target genes like HOXC8 and MYC. JARID1A and 
JARID1B are redundant in H3K4Me3 demethylation 
31
. The loss of JARID1B can be 
functionally compensated by JARID1A.  Hence a combination of JARID1A and 
JARID1B knock down may have a greater effect on MLL target gene expression.  
Cyp33 over expression studies and JARID1B knock down studies suggest that 
JARID1B is a downstream effector of Cyp33. If JARID1B is a downstream effector of 
Cyp33-mediated transcriptional regulation of MLL target genes, knock down of 
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JARID1B should overcome the transcriptional repression resulting from Cyp33 over 
expression. But our results show that Cyp33 over expression, even after the knock down 
of JARID1B, resulted in transcription repression of MLL target genes. From this 
experiment we cannot conclude if JARID1B is a downstream effector of MLL target 
genes. The caveat of this experiment is that JARID1B may not be the only downstream 
effector of Cyp33. As mentioned earlier, there is redundancy in the function of JARID1A 
and JARID1B, and even the knockdown of JARID1B was incomplete. The ideal 
experiment to do would be to over express Cyp33 in a cell line that is null for JARID1A 
and JARID1B (MEF JARID1A-/- , JARID1B -/-). Since Cyp33 can also operate through 
other transcriptional co-repressors like HDAC1at MLL target gene promoters, it may be 
difficult to prove JARID1B as one of the downstream effectors of Cyp33. 
The results from the first aim of this study demonstrated the effects of excess of 
Cyp33 on MLL target gene expression and more specifically on H3K4 trimetylation. The 
biological significance of MLL PHD3 binding to H3K4Me3 and Cyp33 is not known. 
Chang et al., have shown that the abrogation of H3K4Me3 binding to MLL PHD3 
resulted in decreased transcriptional activation of MLL target genes 
30
. MLL is a 
transcriptional regulator of genes involved in hematopoiesis. To determine the biological 
significance of MLL PHD3 binding to H3K4Me3 versus Cyp33, the effect of abrogation 
of binding was studied using an in vitro colony formation assay of hematopoietic 
progenitors. To do so, retroviral transduction of wild type MLL-N, and MLL-N mutants, 
in mouse hematopoietic progenitors was performed. Due to its molecular weight, it is 
difficult to package full length MLL cDNA in a retro viral vector. MLL is proteolytically 
cleaved into MLL-N and MLL-C by TASPASE-1. The PHD3 in MLL-N is the reader of 
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H3K4Me3 and the SET domain in MLL-C is the writer for H3K4Me3. Thus by making 
mutations in MLL-N fragment, instead of full length MLL, will allow us to precisely 
study the effects of abrogation of the reader function without over expressing the writer. 
Furthermore, it will also help to overcome the practical difficulties of using a very big 
construct for retro viral packaging.  
Similar to the PHD fingers of BPTF and ING family members that bind 
H3K4Me3, the conserved aromatic residues in MLL PHD3 form an aromatic cage which 
is the binding pocket for H3K4Me3. Chang et al. have shown that this mutation resulted 
in decreased binding of H3K4Me3 without affect the protein stability 
30
. Hence this was 
chosen as a candidate mutation that would abrogate the binding of MLL PHD3 to 
H3K4Me3. The H3K4Me3 binding site and Cyp33 binding site in MLL PHD3 are 
distinct, but very close to each other. Hence abrogating one binding may affect the other. 
Wang et al. showed that the M1606D mutation abolished the binding of MLL PHD3 to 
Cyp33. However the effect of this mutation on H3K4Me3 binding is not known. Before 
doing any hematopoietic progenitor colony formation assays, the binding of MLL-wt, 
M1585A, and M1606D mutants to H3K4Me3 in vivo was characterized. The results from 
nucleosome Co-IP showed that the MLL-N wt and M1606D mutant co-
immunoprecipitated with nucleosomes trimethylated on H3K4 whereas the M1585A 
mutant MLL-N did not.  
To date, there are no studies on the effect of overexpression of MLL-N wt on 
target gene expression. To study this and to know the effect of MLL-N mutants on target 
gene expression, over expression of MLL-N wt and mutants was induced in MEFs using 
retroviral expression constructs. Hsieh et al., have shown that MLL-C is required for the 
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stability of MLL-N 
74
. Based on this finding, over expressing just the MLL-N fragment 
should result in degradation of excess of MLL-N. Therefore over expression of MLL-N 
wt should not have much effect on target gene expression. Surprisingly, MLL-N wt over 
expression resulted in increased MLL target gene expression both in MEF and in 
hematopoietic progenitors. Yokoyoma et al., have shown that free MLL-C in the nucleus 
is targeted for proteosomal degradation in the cytoplasm 
38
. If the endogenous levels of 
MLL-C are not limiting, and over expression of MLL-N enhances the MLL-N-C holo-
complex formation in the nucleus, then upon over expression of MLL-N there should be 
increased levels of MLL-C in the nucleus. However the results show that MLL-N over 
expression did not influence the protein levels in the nucleus, but resulted in increased 
recruitment of MLL-C and a corresponding increase in H3K4Me3 marks at MLL target 
gene promoters compared to the vector control.  
Unlike MLL-N wt over expression; the M1585A mutation did not result in 
transcriptional activation of MLL target genes. This proves that MLL PHD3 binding to 
H3K4Me3 contributes to the transcriptional activation of MLL target genes. M1585A 
over expression did not result in increased recruitment of MLL-C or an increase of 
H3K4Me3 marks. This suggests that MLL PHD3 binding to H3K4Me3 marks recruits 
more MLL-C and helps in methylation of adjacent nucleosomes leading to transcriptional 
activation of MLL target genes.  
The results from Cyp33 over expression experiments performed in the first aim of 
this study showed a Cyp33 mediated increase in JARID1A/B demethylases at MLL target 
genes and decrease in H3K4Me3 marks at MLL target gene promoters. This result 
suggested a role for MLL PHD3 in protecting H3K4Me3 from demethylation. If that is 
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true, then upon abrogation of MLL PHD3 binding to H3K4Me3, there should be 
increased recruitment of JARID1 histone demethylases and a corresponding decrease in 
H3K4Me3. However, mutating the H3K4Me3 binding site in MLL PHD3 (M1585A) did 
not result in increased recruitment of JARID1B at MLL target gene promoters, while 
showing decreased recruitment of MLLC and H3K4 trimethylation. This result suggest 
that in MEFs (Mll+/+), MLL PHD3 binding to H3K4Me3 is mainly required for 
propagation of H3K4 methyl marks to adjacent nucleosomes and not for the protection of 
H3K4Me3 from JARID1B histone demethylase. Additionally, this result indicates that 
there may be alternative mechanisms that contribute to Cyp33 mediated increased 
recruitment of JARID1B at MLL target gene promoters other than Cyp33 reducing the 
protection of H3K4Me3 by MLL PHD3.  
Cyp33 is a transcriptional repressor of MLL target genes; therefore, by abrogating 
Cyp33 binding to MLL PHD3, we expected a greater increase in MLL target genes 
expression than MLL-N wt over expression. Over expression of M1606D mutant (that 
does not bind Cyp33) resulted in increased expression of MLL target genes, but the effect 
was similar to that of MLL-N wt over expression. This may be because the repressive 
effects of endogenous levels of Cyp33 in the cell may be too small in comparison with 
the transactivation effect of overexpression of MLL-N to be noticed in this experiment. 
Additionally, over expression of the M1606D mutant resulted in decreased recruitment of 
MLL-C and JARID1B when compared to MLL-N wt and M1585A at the Hoxa9 
promoter. The results from the first aim of the study suggested that JARID1B is one of 
the downstream effectors of Cyp33 mediated transcriptional repression of MLL target 
genes. In agreement with this result, mutating the Cyp33 binding site (M1606D) in the 
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MLL PHD3 resulted in decreased recruitment of JARID1B at the HOXA9 promoter. 
Surprisingly, this mutation also resulted in decreased recruitment of MLL-C at the Hoxa9 
promoter. Despite the decreased recruitment of MLL-C, the increase in expression of 
MLL target genes upon over expression of M1606D may be explained by relief of 
transcriptional repression by JARID1B. The reason for the over expression of M1606D 
mutation resulting in decreased recruitment of MLL-C at the HOXA9 promoter is not 
clear. Yokoyama et al., have shown that PHD1, PHD4 and FYRN and FYRC domains 
are required for interaction of MLL-N and MLL-C 
38
. Since the MLL PHD 1, 2 and 3 are 
tandem PHD fingers; the methionine to aspartate mutation in PHD3 may have an effect 
on structure and function of the 3 PHD cassette unit and thus may interfere with MLL-C 
recruitment by PHD1. Additionally, the targeting of proline 1629 by Cyp33 from cis-to 
trans results in a drastic change in the relative positions of PHD1 and PHD4 which are 
located at the opposite ends of this prolyl bond, which may contribute to the recruitment 
of MLL-C by PHD-1 and PHD-4 (Figure 26) 
29,38
. 
          The Hoxa9 and Meis1 genes are expressed at higher levels in hematopoietic 
progenitors and are required to keep the hematopoietic progenitors in an undifferentiated 
state 
106
. Over expression of MLL-N wt and M1606D in hematopoietic progenitors 
resulted in increased expression of MLL target genes like Hoxa9 and Meis1 and also 
increased the colony formation of hematopoietic progenitors when compared to M1585A 
(which does not bind H3K4Me3). This proves that MLL PHD3 binding to H3K4Me3 
contributes to transcriptional activation of MLL target genes allowing the hematopoietic 
progenitors to remain in undifferentiated state and form colonies.  
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The prolyl-isomerase activity of Cyp33 targets P1629 in the linker region between the 
PHD3 and the bromo-domain of MLL.  This cis- trans peptidyl prolyl isomerization 
results in drastic change in conformation and the relative positions of PHD1 and PHD4 
which are located at the opposite ends of this prolyl bond and allows Cyp33 to bind to 
PHD3
29
 . In addition to FYRN and FYRC domains of MLL; the PHD1 and PHD4 are 
also required for mediating the interaction between MLL-N and MLL-C
38
. Abrogation of 
MLL PHD3 binding to Cyp33 PHD3 (M1606D) may have an effect on the structure and 
the function of the 3 PHD cassette unit and thus may interfere with MLL-C recruitment 
by PHD1.   
 
 
Figure 26: Putative model for the effect of Cyp33 binding to MLL PHD3 on 
recruitment of MLL-C 
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 Cdkn1b is a transcriptional target of MLL. Xia et al., have shown that the 
transcriptional outcome of MLL overexpression depends on the cell type 
11
. Concordant 
with Xia et al. results, MLLN over expression showed cell-type specific transcriptional 
outcome of Cdkn1b. As mentioned earlier, MLL-N wt over expression resulted in 
transcriptional activation of Cdkn1b in MEFs, whereas, there was no effect in 
hematopoietic progenitors. In contrast to MLL-N wt, over expression of M1585A in 
hematopoietic progenitors resulted in decreased expression of self-renewal genes like 
Hoxa9 and Meis1, but showed increased expression of cell cycle inhibitors like Cdkn1b 
and Cdkn1a. Furthermore, over expression of M1585A in hematopoietic progenitors 
resulted in drastic reduction of colony formation. Fast proliferating cells like 
hematopoietic progenitors have lower levels of Cdkn1b whereas growth arrested cells 
like terminally differentiated cells have higher levels of Cdkn1b expression 
109
. Cdkn1a 
expression increases upon induction of differentiation 
109
. Taken together, the decreased 
expression of self-renewal genes, increased expression of cell cycle regulators and 
decreased colony formation suggesting that M1585A over expression may inhibit the 
proliferation and/or induce differentiation of hematopoietic progenitors.  
The wild type MLL allele is required for MLL-AF9 induced leukemogenesis and 
is also required for the survival and maintenance of MLL-AF9 transformed leukemic 
cells. The wild type MLL is recruited to HOXA9 and Meis1 promoters and is required for 
trimethylation of H3K4 at HOXA9 and Meis1 promoters, thus contributing to their 
transcriptional activation in MLL-AF9 transformed leukemia cells 
20
. MLL fusions lack 
PHD fingers. We hypothesized that MLL PHD3 (encoded in the wild type MLL allele) 
binding to H3K4Me3 contributes to the transcriptional activation of MLL target genes in 
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MLL-AF9 transformed cells. The results from this experiment showed that MLL-N or 
mutants over expression did not have an effect on colony formation of MLL-AF9 
transformed hematopoietic progenitors. The MLL fusion protein constitutively activates 
the transcription of Hoxa9 and Meis1. Most common fusion partners of MLL; AF9, AF4, 
ELL and ENL are present in super elongation complex (SEC) along with transcription 
elongation factor like P-TEFB. The SEC is implicated in transcriptional activation of Hox 
genes in MLL rearranged leukemia 
110
. The common fusion partners like AF-9, AF-10, 
and ENL are found in complex with DOT1L, a H3K79 methyl transferase. The aberrant 
recruitment of DOT1L  to MLL target promoters constitutively activates the transcription 
of Hoxa9 
111–114
. Hence the effects of MLL-N wt or mutants may be masked by the very 
high levels of over expression of MLL-AF9 in mouse hematopoietic progenitors. In the 
future, to determine the role of MLL PHD3 binding to H3K4Me3, we may have to 
partially inhibit DOT1L in MLL-AF9 transduced hematopoietic progenitors and then 
study the effects of abrogation of MLL PHD3 on leukemogenesis.  
The results from the experiments performed in mouse hematopoietic progenitors 
showed that MLL PHD3 binding to H3K4Me3 contributes to the transcriptional 
activation of MLL target genes in hematopoietic progenitors and is required for 
hematopoietic progenitor proliferation. Thus we have identified a novel biological 
function for MLL PHD3 binding to H3K4Me3, this opens up many avenues for further 
studies. Chromosomal amplification of MLL is frequently seen in MDS, AML, ALL, and 
specifically in therapy related leukemia and is associated with poor prognosis 
115–118
. 
Patients with MLL amplification over express the wild type allele and show increased 
expression of HOXA9 and Meis1. Hence disrupting the interaction between MLL PHD3 
 107 
 
 
 
and H3K4ME3 in MLL amplified leukemia may be a potential treatment option 
115
. MLL 
is haplo-insufficient, given the importance of MLL in fetal and adult differentiation, 
development and cell cycle regulation, a heterozygous mutation that disrupts the binding 
of MLL PHD3 to H3K4Me3 may prevent MLL from performing its functions resulting in 
developmental disorders or diseases. Due to the enormous size of the MLL gene, the 
mutation studies on MLL are limited. However with the advent of next generation 
sequencing, it will be interesting to determine if the mutation of MLL PHD3 binding to 
H3K4Me3 occurs frequently in any developmental disorders. 
In summary, over expression of Cyp33 caused increased H3 density, decreased 
H3Ac, increased recruitment of JARID1 histone demethylases, and decreased H3K4Me3 
at MLL target gene promoters. As a consequence, Cyp33 over expression resulted in 
transcription repression of MLL target genes. Abrogation of binding of H3K4Me3 in 
MLL PHD3 resulted in decreased recruitment of MLL-C, decreased in H3K4Me3 levels, 
decreased MLL target gene expression and decreased expansion of hematopoietic 
progenitors when compared to MLL-N wt, demonstrating that MLL PHD3 binding to 
H3K4Me3 contributes to the transcriptional activation of MLL target genes.  
Collectively, the results from this study points us to a model wherein MLL PHD3 
binding to H3K4Me3 helps MLL-C to trimethylate H3K4 on adjacent nucleosomes, 
contributing to transcriptional activation of MLL target genes, as shown in the model 
(Figure 27). Whereas, excess of Cyp33 results in increased recruitment of JARID1A/B at 
MLL target gene promoters in a PPIase- dependent manner resulting in active 
demethylation of H3K4Me3, resulting in target gene repression (Figure 28). Thus MLL 
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PHD3 functions as a part of a molecular switch in transcriptional regulation of MLL 
target genes. 
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Figure 27: Model for the function of the MLL PHD3-H3K4Me3 interaction 
 
 
 
 
 
 
 
Figure 28: Model for effect of excess of Cyp33 on trimethylation of H3K4 at MLL 
target gene promoters 
 
 
 
 
 
 
 
 
 
 
MLL is recruited to its target promoters by several mechanisms. The binding of MLL 
PHD3 to H3K4Me3 may be one of the mechanisms. Thus the MLL PHD3 may help 
target the SET domain of MLL-C to trimethylate adjacent histones. This maintains the 
H3K4Me3 marks at the target promoters leading to sustained expression of Hoxa9 and 
Meis1 in hematopoietic progenitors.  
 
 
 
Excess of Cyp33 results in increased recruitment of JARID1 A/B histone 
demethylases to MLL1 target gene promoters, resulting in decrease in H3K4Me3 
marks at MLL1 target gene promoters leading to transcriptional repression of MLL1 
target genes. The mechanism by which Cyp33 binding to MLL stimulates JARID1A/B 
recruitment to chromatin is not known. However, the PPIase activity of Cyp33 is 
required for the recruitment of JARID1B to MLL target gene promoters. JARID1B 
binds DNA in a sequence specific manner, and binds H3K4Me3.  
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